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Both lung cancer and medulloblastomas are treated with ionizing radiation (IR) in 
combination with surgery or anticancer agents. Although the survival rates have 
improved over the past decades, both of these cancer types still demonstrate a poor 
overall survival and long-term side effects are common, especially for 
medulloblastoma in children. One of the main hurdles for successful treatment 
outcome in cancer patients is the acquired resistance to treatment. As a stress 
mechanism in response to IR, cancer cells secrete several growth factors that can act 
in an auto- and paracrine manner and, thereby, can support tumor growth. One of 
these factors is placental growth factor (PlGF) which is mainly involved in tumor 
angiogenesis.  
PlGF expression is increased in cancer patients in response to various treatment 
forms. Even though its role in pathological angiogenesis has been shown before, not 
much attention has been directed to PlGF and our knowledge about the role of PlGF 
for treatment resistance is limited. Clinical trials with neutralizing antibodies targeting 
PlGF in combination with other anti-cancer agents was discontinued due to lack of 
improved survival in previously treated patients. The regulation of PlGF in response 
to ionizing radiation and its role for the treatment response to radiotherapy has not 
been investigated so far. Thus, further research focusing on PlGF as a potent molecular 
target as part of a combined treatment modality with ionizing radiation is needed.  
In this PhD thesis, we investigated PlGF expression and secretion in several cancer cell 
lines and provide insight into IR-induced regulation of PlGF. Our additional 
experiments focused on determining the role of PlGF as a rescue mechanism in 
response to IR.  
Based on results from our bioplex cancer biomarker assay, we investigated PlGF 
expression and secretion at early and late time points in response to increasing doses 
of IR in multiple cancer cell lines. Early PlGF expression correlated with early 
secretion in p53 wildtype cells. Delayed PlGF expression and secretion in p53 mutated 
cells could depend on other transcription factors, such as hypoxia inducible factors 
(HIFs) and subsequent downstream signaling pathways. The mechanism behind IR-
induced PlGF signal transduction pathway is not fully understood. In order to verify 
PlGF regulation, we performed mechanistic investigations by genetic and 
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pharmacologic targeting of p53. Our results demonstrated a clear and specific PlGF 
regulation by wildtype p53. In parallel, the expression and secretion of PlGF alone, 
and in combination with irradiation under hypoxia was investigated to show a 
potential differential regulation of PlGF in p53 mutated cells by HIF-1α. We show 
increased PlGF secretion under hypoxic conditions in combination with IR. However, 
this was abolished in cells treated with the HIF-1α inhibitor BAY 87-2243.   
The second part of the project investigated the protective role of PlGF in tumor 
angiogenesis and radiation therapy.  
In our in vitro experiments, we investigated the paracrine effect of PlGF in a migration 
assay using PlGF wildtype or knockout cells. We assessed the migratory capacity of 
human umbilical endothelial vein cells (HUVECs) towards PlGF-wt and PlGF-ko cells 
in response to IR. Increased migratory capacity of HUVECs towards irradiated PlGF-
wt cells versus PlGF-ko cells was observed.  We also investigated the role of PlGF on 
the formation of the tumor vasculature and tumor radiosensitivity in vivo. Mice 
bearing PlGF-ko tumors demonstrated decreased vascular integrity in response to 
irradiation and increased radiosensitivity. 60% of mice with PlGF-ko tumors regressed 
completely after single high dose irradiation.  
In conclusion, my PhD project provides first insights into genetic background-
dependent regulation of PlGF as part of a treatment response to ionizing radiation. 
The obtained results also demonstrate an important IR-induced paracrine role of PlGF 
in vessel protection and treatment resistance. Based on our in vitro and in vivo results, 
we propose PlGF to be of translational interest in tumors with wildtype p53 
background and a promising target for a combined treatment modality in combination 
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1.1 Cancer overview 
 
Cancer is a malignant neoplasm – a disease involving genomic alterations and 
transformation of normal cells into tumor cells that can grow uncontrollably and 
invade other organs through metastasis [1, 2]. The incidence of cancer is due to 
mutations that are acquired through incorrect DNA replication during stem cell 
division, through environmental factors such as air pollution, sun, lifestyle (smoking, 
diet) or infections (bacterial and viral) and a limited amount of inherited mutations. 
[3, 4]. Mutations in oncogenes and tumor suppressor genes, leading to gain of function 
and loss of function respectively, indicate that the disease is a multistep process. Most 
of these mutations are called passenger mutations as they do not alter the cell’s 
functions. However, certain mutations that affect essential functions of a cell are called 
driver mutations and can lead to cancer.  
Tumors can arise in almost every organ and are divided into two groups: benign and 
malignant (cancer). Compared to benign tumors, which are harmless, malignant 
tumors are metastatic, meaning they have the ability to disseminate from the primary 
site and invade a distant organ, and are major contributors to morbidity and mortality 
[5]. We are familiar with more than 100 types of cancer and their organ-specific 
subtypes [1]. Cancers obtain their names according to their origins and can exist either 
in solid form where it grows in an organ (e.g. carcinoma), such as lung or affect the 
blood system (leukemia). Carcinomas are the most common type of cancer arising 
from epithelial cells in respiratory system, breast, head and neck and many more. 
Sarcomas arise in the mesenchymal cells of muscle, bone or connective tissue. 
Hematopoietic cancers are blood cancers and include leukemia and lymphoma. 
Melanoma and cancers of neuronal system fall into category of neuroectodermal 
cancers.  
The International Agency for Research on Cancer estimated 18.1 million new cancer 
cases and 9.6 million cancer deaths worldwide in 2018 using GLOBOCAN 2018. 23.4% 
of these cases were estimated to occur in Europe alone. For both women and men 
combined, lung cancer is the most common cancer type (11.6%) with 2.1 million new 




In 2000 and 2011, Douglas Hanahan and Robert Weinberg published two separate 
articles, providing a list of principles that are acquired by tumors in the process of 
carcinogenesis with the latter article having an updated version with a total of 10 
hallmarks [1, 7]. These hallmarks have been used in basic and translational research 
as a basis for a better understanding of cancer and for improving the treatment 
strategies. Normal cells are able to regulate stimulatory and inhibitory signals and 
therefore maintain homeostasis. Sustaining proliferative signaling is the most 
important feature of cancer cells where they can deregulate the homeostasis by 
increasing the production of growth factors from themselves or the surrounding cells. 
Moreover, downstream signaling pathways can also be constitutively activated 
independent of growth factors. Additionally, cancer cells are able to evade growth 
suppressors by acquiring mutations in different tumor suppressor genes. Apoptosis is 
one form of a programmed cell death that is triggered in response to various stress 
signals. In cancer cells, due to increased oncogenic signaling, several imbalances occur 
in apoptosis inducing pathways and therefore can resist cell death. In order to create 
a tumor, cancer cells can enable replicative immortality by extending the telomeres 
using active telomerase. Cancer cells induce angiogenesis by increasing the expression 
of several pro-angiogenic factors, such as vascular endothelial growth factor (VEGF). 
This in turn leads to new vessel formation and therefore cancer cells can supply 
themselves with oxygen and nutrients.  By modifying the proteins involved in cell-cell 
and cell-extracellular matrix (ECM) adhesion, cancer cells are able to activate 
invasion and metastasis related pathways. Usually, cancer cells acquire mutations in 
genes involved in detection and repair of DNA damage. These mutations result in 
genomic instability and growth advantage. Pro-tumorigenic proteins, such as 
angiogenic and growth factors in the tumor microenvironment, are involved in tumor-
promoting inflammation. Deregulating cellular energetics from oxidative 
phosphorylation to aerobic glycolysis supplies tumor cells with glycolytic 
intermediates for different metabolic pathways. Cancer cells are able to avoid immune 
destruction by upregulating immune inhibitory surface molecules or recruiting 
immune suppressive cells. Figure 1 shows a short summary of these hallmarks and 




Figure 1. Hallmarks of cancer and their treatment strategies. Cancer cells possess 
several hallmarks in order to grow and survive. Treatments strategies of cancer is based on 
these hallmarks and the targeting each of these with the appropriate drugs. Figure adapted 
from [7].       
 




X-rays were discovered in 1895 by Roentgen and shortly after radiation was used to 
treat cancer for the first time [8]. Over the years, there were major developments that 
lead to a drastic increase in benefits [9, 10]. These developments include advances in 
technology and a better understanding of molecular pathways involved in treatment 
response [11-16]. 
Ionizing radiation (IR) is a process where the absorption of radiation leads to ejection 
of one or more electrons from an atom or a molecule. These high energy, accelerated 
electrons have a high probability to interact with matter, induce downstream 
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ionizations (“electron splash” by secondary electrons) thereby leading to breakage of 
chemical bonds. Radiation can either be directly or indirectly ionizing. Charged 
particles (electrons and protons) are directly ionizing, meaning each particle has 
enough energy to directly disrupt an atom. Electromagnetic radiations (x-rays), on the 
other hand, are indirectly ionizing and can only produce damage when they are 
absorbed in a material, can give up their energy to the (ejected) electron of a molecule, 
generating an electron splash and eventually producing free radicals. For example, the 
hydroxyl radical is highly reactive and can diffuse to DNA to induce critical damage. 
In order to be biologically active and considered ionizing, the electromagnetic 
radiations should have an energy of at least 124eV. A dose of 1Gy (1J/kg) can induce 
40 double-strand breaks (DSB), 1000 single-strand breaks (SSB) and 1000 base pair 
damages [17].  
Radiation therapy (RT) is an essential and effective method for cancer treatment with 
survival and palliative benefits for patients and is widely used for management of 
cancer [18-22]. The aim of RT is to distribute the optimal dose to the tumor in order 
to kill the cancer cells and to shrink the tumor while sparing the normal tissue. Usually, 
RT is combined with surgery and chemotherapy. In case of inoperable or recurrent 
tumors, RT is the choice of treatment [23]. Approximately 50% of all cancer patients 
are treated with RT [24, 25] with curative or palliative aim [23, 24, 26-29]. Despite a 
remarkable progress in RT, there is still a need to improve the curative rate.   
RT is typically applied in multiple fractions over several weeks in order to increase the 
therapeutic index [27]. Different types of radiation sources, such as photons or 
protons, can be used to improve the efficacy of the treatment, to effectively kill tumor 
cells while sparing the normal tissue (biological effective dose) [10, 30]. Radiation can 
be delivered either by external beam radiation therapy or with radioactive material 
placed close to cancer cells (brachytherapy) inside the body. Different types of 
radiation have different linear energy transfer (LET). LET is the number of ionizations 
per unit distance caused by radiation as it crosses the living tissue. LET, fractionation, 
dose rate, radiosensitivity of tissues and total dose are the determinants of biological 
effectiveness [31]. X-rays, gamma rays and beta particles are all low LET radiations 
and deposit a small amount of energy per ionizing event. Negatively charged 
(electrons) or positively charged (protons, heavy ions) particles deposit more energy 
on the target area (Bragg peak) and can cause more relevant biological effects. 
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Nevertheless, tumors can resist radiation induced damage due to intrinsic or acquired 
resistance to therapy, tumor burden and repopulation during the course of treatment 
[32]. Either alone or in combination with surgery and/or chemotherapy, high doses of 
ionizing radiation can achieve almost 100% of tumor control probability (TCP) [11]. 
However, at the same time, healthy tissue is also exposed to radiation, which leads to 
increased normal tissue complication probability (NTCP) and limited treatment 
success rates. Therefore, the major goal of experimental research in radiation oncology 
is to extend the therapeutic window by reducing the normal tissue toxicity and at the 
same time increasing tumor control [23, 33]. 
 
Figure 2. Mechanisms of ionizing radiation (IR). IR can damage the DNA either 
directly or indirectly by generating reactive oxygen species (ROS) from water molecules inside 
the cell. Types of DNA damage: single-strand break (SSB), double-strand break (DSB), cross-
linking, base damage. Figure adapted from [34]. 
 
1.2.1.1 The 5 R’s  
 
The 5 R’s of radiobiology have played an important role not only in the development 
of safe, precise and effective treatment regimens, but also in our understanding of 
biological effects of radiation. They have also been involved in characterization of 
tumor and normal tissue response to fractionated RT. The following list of 5 R’s [35] 




Repopulation: each fraction of RT decreases the number of surviving tumor cells. 
However, the surviving cells can grow and repopulate between the fractions. 
Repopulation is evident three to four weeks after the start of conventional RT and is 
one of the causes to treatment resistance.  
Repair: IR ejects electrons from molecules within the cells, leading to their collision 
with DNA and further ionizations. This can induce single-strand or double-strand 
breaks on the DNA (SSB and DSB, resp.), the latter particularly difficult to repair.  
Redistribution: radiosensitivity of cells varies according to the cell cycle. Cells in S 
phase are more resistant to RT than cells in late G2/M phase. Moreover, cells are able 
to repair damage differently in the various phases of the cell cycle. The surviving cells 
after RT redistribute to next phases of the cell cycle.  
Reoxygenation: tumors contain a mixture of normoxic and hypoxic areas. 
Reoxygenation refers to the process where hypoxic cells become oxygenated after RT. 
Hypoxic cells are less sensitive to RT, which leads to treatment failure. Normoxic cells, 
on the other hand, are more sensitive to RT and the RT-induced damage is more 
permanent.   
Radiosensitivity: intrinsic radiosensitivity is genetically determined and varies 
between tissues depending on the proliferation, function and ability of cells to undergo 
a mode of programmed cell death. Susceptibility to e.g. apoptosis contributes to 




Chemotherapy is a systemically-applied therapy, meaning besides killing cancer cells, 
chemotherapy will also affect normal tissues and will therefore lead to high levels of 
normal tissue toxicities and treatment side effects. Nevertheless, chemotherapy is 
widely used in the clinics in combination with surgery or radiotherapy. Based on their 
mechanism of action and target, chemotherapeutic drugs are divided into the 
following groups: 
Alkylating agents: Alkylating agents are reactive compounds with the ability to modify 
the structure of different molecules (such as DNA or proteins) by transferring alkyl 
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carbon groups onto them. These compounds react with nitrogen or oxygen atoms of 
DNA and generate irreversible covalent bonds, which later disrupts the DNA processes 
(e.g. DNA replication) [36-38]. 
Anti-metabolites: even though anti-metabolites may have different actions that either 
lead to cytotoxicity or radio-sensitization, they all target DNA replication. Based on 
this, anti-metabolites can be divided into two groups: a) agents inhibiting 
deoxyribonucleotides for replication (e.g. fluorouracil) and b) agents becoming false 
substrates for DNA polymerases (e.g. gemcitabine) [39].  
Topoisomerase inhibitors: Topoisomerases are enzymes essential for transcription 
and replication and can regulate DNA supercoiling and entanglements by different 
mechanisms. Topoisomerase inhibitors are powerful and selective drugs used as 
anticancer therapy. Inhibition of topoisomerases leads to formation of abnormal DNA 
structures that results in cell cycle arrest [40].     
Microtubule interfering agents: drugs in this category act on microtubules, either 
stabilizing (e.g. paclitaxel) or disrupting (e.g. vincristine) the microtubule polymers. 
Impaired microtubule structure and function leads to cell cycle arrest and cell death 
[41].     
 
1.2.3 Targeted therapy 
 
The aim of targeted therapy is to inhibit or modify specific signaling pathway and 
proteins involved in tumor growth. Targeted therapy is divided into two categories: 1) 
small molecules that can pass through the cell membrane and interfere with targets 
inside the cells (tyrosine kinase inhibitors: imatinib, gefitinib), 2) monoclonal 
antibodies that are not able to enter the cells and can target specific proteins on the 
cell surface (bevacizumab, cetuximab). Monoclonal antibodies can also be delivered as 
antibody-drug conjugates (ADCs). In this case, when an antibody binds to its target on 
cancer cells, the conjugated drug is incorporated and released into the cancer cell [42-
44]. It is important to identify specific molecular markers expressed by cancer cells as 
targets for either of these categories in order to increase the therapeutic window so 
that patients will benefit from this type of therapy. Overall, targeted therapy is 
associated with improved effect on the tumor level and decreased toxicity.  
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Figure 3. A model for use of targeted therapy. Targeted therapy can either focus on 
targets in the tumor microenvironment or on targets within the cancer cells. Targeted 
therapies directed against targets in the tumor microenvironment include blood vessels (1) 
and the immune system (2). Signaling pathways within the cancer cells can be targeted by 
antibodies against extracellular domain of transmembrane receptors (3) or using inhibitors 
against their intracellular tyrosine kinase domains (4). Other targets include proteins involved 




Over the last few years, immunotherapy has become of great interest due to its ability 
to treat certain cancer forms either through immune activation or suppression. 
Immunotherapy is not as widely used as other therapies mentioned here. However, 
some immunotherapies are approved for cancer treatment and several 
immunotherapies are being investigated in clinical trials. Immunotherapeutic drugs 
are categorized into two groups:  
1) drugs blocking negative regulatory signals and thereby inhibiting immune evasion: 
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) is expressed on T cells in very 
low levels, but is upregulated upon T cell receptor (TCR) activation and peptide 
complex formation and acts as a negative regulatory receptor [45]. CTLA-4 competes 
with its homolog CD28, a costimulatory receptor on T cells, for the same ligands 
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(CD80 and CD86) [46]. Anti-CTLA-4 monoclonal antibodies have shown incredible 
clinical results with regard to tumor regression in advanced melanoma. These 
antibodies disrupt CD28 activation and deplete regulatory T cells (Tregs) [47].     
Programmed cell death protein 1 (PD-1) is a co-inhibitory receptor with high 
expression on activated T cells, B lymphocytes and natural killer (NK) cells [48]. Its 
expression is induced upon TCR-peptide complex formation in the effector phase of 
the immune response. It has two ligands (PD-L1 and PD-L2) that are expressed in low 
levels in healthy tissues. Binding of PD-1 to PD-L1 on tumor cells may provide the 
tumor cell with resistance to cytotoxic T-lymphocytes (CTLs) and apoptosis induced 
by the Fas pathway. Increased PD-L1 expression has been reported in melanoma, head 
and neck cancer, non-small cell lung cancer (NSCLC) and breast cancer subsequently 
leading to increased benefit with PD-1 axis blockers [47].  
2) drugs stimulating immunogenic pathways: Vaccines enhancing the antigen 
presentation, oncolytic viruses and exogenous cytokines are all part of immune-
stimulatory therapies. Activation of phosphoinositide 3-kinase (PI3K) and mitogen-
activated protein kinase (MAPK) increase PD-L1 expression in preclinical studies. PD-
L1 expression is also increased in response to proinflammatory cytokines such as 
interferon gamma (IFN-γ) and IL-4. Even though many immune-stimulatory drugs 
targeting immune checkpoint pathways have shown promising clinical results, a 
majority of patients do not benefit from these drugs due to heterogeneous 














Figure 4. Blocking PD-1, PD-L1 or CTLA-4 in tumor immunotherapy. Recognition 
of antigens by T-cell receptor activates T cells. A second signal through costimulatory 
molecules is required for a full activation. These molecules can either lead to positive or 
negative T cell regulation depending on where they bind.  Figure adapted from [50].  
 
Most of the cell lines used in this project are either medulloblastoma (section 1.3) or 
lung cancer (section 1.4) cell lines. Both of these tumor entities are treated with RT in 
the clinics and show increased placental growth factor (PlGF (see section 1.5.4)) levels 





In 1925, doctors Harvey Cushing and Percival Bailey introduced the term 
“medulloblastoma” for the very first time. Patients with this tumor were usually 
subjected to surgery, which was the only treatment for these patients at that time and 
presented dismal outcomes [51, 52]. The survival rate in medulloblastoma patients 
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increased significantly after the introduction of craniospinal irradiation by Paterson 
and Farr in 1953, even though young patients suffered from severe side effects. In 
order to improve this, surgery and radiation therapy were combined with 
chemotherapy starting in the 1970s [51]. 
Currently, medulloblastoma is one of the most frequent malignant childhood brain 
cancers, responsible for 8-10% of all childhood brain tumors. It arises in the 
cerebellum and is classified as a grade IV tumor by World Health Organization 
(WHO). Each year 1.5-2 cases/100 000 people are reported, most cases occurring 
between 5-7 years of age and affects boys almost two times more than girls [52]. 
Several studies have profiled the genetic mutations of medulloblastoma, identifying 
mutated genes and correlating them to the specific molecular subgroups of 
medulloblastoma [53-56]. The major problems of medulloblastoma are 1) the lack of 
effective drugs due to few targets, 2) the heterogeneity of the disease within a subgroup 
and 3) resistance to therapies due to acquired genomic alterations during the disease 
[57].  
Medulloblastomas are divided into four molecular subgroups with distinct 
transcription profiles and clinical outcomes: wingless (Wnt), sonic hedgehog (SHH), 
Group 3, and Group 4. Some evidence suggest that prognosis is associated with the 



















Figure 5. Medulloblastoma subgroups and their characteristics. Medulloblastoma 
has four different subtypes with specific genetic expression, prognosis and survival rates. 
Figure adapted from [59]. 
 
 
1.3.1 Wingless  
 
This molecular subgroup is the least common, responsible for approximately 11% of 
medulloblastoma and affects both sexes to the same extent. Usually patients are 6-10 
years at the time of diagnosis and have a positive prognosis with 5-year survival almost 
90% [57]. Tumors show activated WNT signaling pathway with monosomy 6 and point 
mutation in β-catenin (CTNNB1) [55]. WNT signaling is involved in variety of 
processes, such as angiogenesis in CNS, bone formation and regulation of other 
signaling pathways. Therefore, targeting the interaction between CTNNB1 and CREB 
binding protein (CREBBP) is being evaluated. It is worth noting that targeting WNT 
pathway might also lead to resistant tumors, as WNT signaling might improve the 






1.3.2 Sonic Hedgehog 
 
The Sonic hedgehog (SHH) subgroup affects mostly the youngest and the oldest 
patients with bimodal distribution. This subgroup is named after the most dominating 
signaling pathway in these tumors, namely SHH and accounts for 25% of all 
medulloblastoma cases [57]. The survival rate in this group largely depends on the 
TP53 status of the tumor, with better 5-year survival rate for TP53 wild-type tumors 
compared to TP53 mutated tumors. TP53 mutated tumors are resistant to therapies 
and have increased MYCN amplification [60]. Other mutations in this subgroup also 
include the SHH receptor smoothened (SMO) [54]. Additionally, SHH 
medulloblastoma shows different gene expression profiles depending on the age of the 
patients [61]. The best way to treat this subgroup of medulloblastoma is to use SMO 
inhibitors, such as Vismodegib, as long as the mutations observed are upstream of the 
receptor. However, this type of treatment is most favorable for adult patients [57].  
 
 
1.3.3 Group 3 
 
Expression of MYC, deletion in chromosome 11 and isochromosome 17q among other 
genetic abberations are signatures of Group 3 medulloblastomas [53, 56, 62]. 25% of 
all cases belong to this subgroup and it has the worst prognosis out of all groups with 
5-year survival rate of 20% [56]. 50% of Group 3 tumors are mostly diagnosed at 
metastatic state and are constantly in focus for potential therapies because of the 
disease outcome [63, 64]. For example, cycline-dependent kinase 4/6 (CDK4/6) 
inhibitor Palbociclib, approved for treatment of breast cancer, is in clinical trial for 
medulloblastoma patients since MYC overexpressing tumors rely on CDK4/6 for their 
proliferation and migration. Compared to WNT and SHH groups, p53 mutations are 
absent in this subgroup [60].  
 
1.3.4 Group 4 
 
This is the most common subgroup with 35% of all cases, although not much is known 
about Group 4 medulloblastomas. It consists of chromosomal copy number variations 
and i17q. However, compared to Group 3, patients in Group 4 benefit from i17q or loss 
of chromosome 11. Overall, depending on the risk group, patients in this subgroup 
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have great prognosis that can go up to 95% [65]. Some research groups suggest that 
inflexible epigenetic regulations could be a signature of this group [66, 67]. 
 
1.3.5 Treatment of medulloblastoma 
 
Treatment of medulloblastoma is based on the risk criteria, meaning whether it is a 
standard-risk (SR) or a high-risk (HR) patient. Children over 3 years of age without a 
metastatic disease and a tumor less than 1.5cm2 are considered as SR, whereas the rest 
are HR. HR patients usually present a metastatic disease and have poor prognosis 
[68]. A combined treatment modality is used for treatment of children older than 3 
years, which is surgical resection followed by chemotherapy and craniospinal RT [69]. 
Usually, patients receive combined chemotherapy of cyclophosphamide, cisplatin and 
vincristine [57]. Younger children are subjected to surgery and high-dose 
chemotherapy without irradiation, which can give up to 75% 5-year survival depending 
on the subgroup [69, 70]. 
However, the treatments have severe side effects including cognitive and endocrine 
dysfuntion, hearing loss and increased cancer risk [71, 72]. Although 
medulloblastomas are radiation sensitive, this type of treatment leads to loss of up to 
40 IQ points [73]. 
There is an urgent need for alternative treatment options. Lately, the focus has been 
on targeted therapy using drugs against molecules that have a driving role in 
medulloblastoma. One of these targets is Notch signaling pathway, which is involved 
in survival and proliferation of neuronal cells [74]. Other factors involved in 
medulloblastoma formation are VEGF, platelet-derived growth factor (PDGF) and 
cyclooxygenase 2 (COX2) among others revealed by preclinical research [25]. Clinical 
trials are performed combining targeted therapy with chemotherapy or anti-
angiogenic agents [69].  
 
 1.4 Lung cancer 
 
The most common cause of cancer-related deaths in the world is due to lung cancer 
[6].  85–90% of lung cancers are non-small-cell lung cancer (NSCLC) with 5-year 
survival rate approximately 16%, while the rest fall into small-cell lung cancer (SCLC) 
[75]. NSCLC is characterized into subtypes based on their histology and genotype, with 
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distinctive features and prognoses. There are two subtypes of NSCLC: 
adenocarcinoma arising in the distal airways and squamous cell carcinoma (SCC) 
more frequent in proximal airways [76]. The two subtypes are distinguished by 
immunostaining for cytokeratin 5 and 6 or specific transcription factors [76, 77].  
Radiotherapy plays an important role in treatment of both early-stage and advanced 
stage NSCLC and SCLC with curative or palliative intent. Patients with inoperable 
early-stage NSCLC are treated with stereotactic ablative radiotherapy (SABR) with 
curative intent using several modern imaging technologies [78]. Post-SABR failures 
include local recurrence, lymph node failures and development of distant disease. 
Further therapies for these patients are usually radiotherapy and chemotherapy [79]. 
Locally advanced NSCLC is still difficult to treat showing local and distant failures after 
chemoradiotherapy [80]. However, the recommended treatment for these patients is 
still conventional fractionated chemoradiotherapy [78]. SABR (1-5 fractions) 
combined with chemotherapy is also used as a promising treatment method for early-
stage SCLC showing good local control rate [81]. 
Green and colleagues demonstrated that lung tumors do not only differ in histology, 
but also in their response to different drugs by showing that lung SCC was more 
sensitive to nitrogen mustard, while SCLC responded best to cyclophosphamide [82]. 
In 2002, a randomized clinical trial assessed the efficacy of frequently used 
chemotherapeutic treatments (cisplatin plus either paclitaxel, gemcitabine or 
docetaxel, and carboplatin and paclitaxel) showing no survival advantage with any of 
the treatment regimens compared to each other [83]. 
Lung cancer was accepted to be a heterogeneous disease already in the 1950s. 
However, treatment options remained unchanged until 2004 when it was accepted 
that mutational status of the disease plays an important role in treatment response. 
For example, epidermal growth factor receptor (EGFR) mutation and the response to 
gefitinib lead to identification of a specific group of patients [84, 85]. Additionally, 
high response rates and high disease-control rates are achieved with erlotinib, 
gefitinib, and afatinib in patients with EGFR mutations, and with crizotinib and 
ceritinib in patients with anaplastic lymphoma kinase (ALK) translocations [85]. 
Although patients with ALK translocations respond >70% to crizotinib treatment, 
most of them relapse within the first year of treatment. Erlotinib also shows similar 
responses in patients EGFR mutations, nevertheless the survival rates are low [85]. 
Resistance to these treatments include mutations, gene amplifications or alternative 
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splicing of the target gene or activation of other oncogenic pathways (e.g. BRAF 
mutation, HER2 amplification etc.). Furthermore, insufficient exposure to the drug 
due to hindered interactions and pharmacokinetic differences can also contribute to 
resistance mechanisms [86, 87].  
Resistance mechanisms are not exclusive and several resistance mechanisms can exist 
in one tumor [87]. To overcome this hurdle, multiple therapies are used in 
combination. Nevertheless, the diversity of pathways interacting and the sensitivity of 
these pathways to different drugs make this task rather difficult.  
By producing tumor antigens, RT can also stimulate the immune system, promote 
anti-tumor T-cell response and possibly lead to abscopal effects causing regression of 
other lesions. There is an ongoing research about the optimal dose of RT and its 
fractionation and the combination with immunotherapies [88]. Anti-tumor immune 
responses to treat several types of cancer, including NSCLC, have been of interest for 
many years [89]. However, there have been limitations due to immune-evasion 
mechanisms in the tumor, such as secretion of immunosuppressive cytokines or 
upregulation of immune-checkpoint proteins. Additionally, activating mutations in 
EGFR pathway have shown to increase PD-L1 expression [90]. Tumor cells express 
PD-L1 on the cell surface to inhibit eradication by T cells that express PD-1. Clinical 
trials blocking PD-1–PD-L1 interaction have shown promising results in a subgroup of 
patients [85]. Nivolumab, a PD-1 antibody approved for patients with metastatic lung 
SCC, showed prolonged overall survival in previously treated patients compared to 
docetaxel treated patients in a phase III trial [85]. At the moment, there is a need to 
define NSCLC subsets based on the immune response and further investigations on 




Figure 6. Summary of treatment options for advanced stage NSCLC. Depending 
on the genetic expression, different subtypes of lung cancer are treated accordingly. Figure 






1.5.1 Normal angiogenesis 
 
Blood vessels are necessary for supplying oxygen and nutrients, and removing the 
metabolic waste in living organisms. During embryonic development, the vascular 
network develops through vasculogenesis, a process where vessels are formed de novo 
from angioblasts. Angioblasts proliferate and form a network of vessels which later 
serves as a support. These network of vessels are then modified by the sprouting and 
branching of vessels leading to angiogenesis, the formation of new vessels from 
preexisting ones [91, 92]. Normal angiogenesis has a central role in wound healing, 
ovarian cycle, organ perfusion and establishing an adequate vessel support for growing 
organs during embryonic development [93]. Under physiological conditions, blood 
vessels remain dormant and do not form new vessels. However, irregularities in 
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angiogenesis are linked to many disorders, including ocular neovascularization and 
cancer [92, 94, 95].   
Briefly, the following steps are involved in angiogenesis: 1) pericytes are detached from 
the blood vessel and different proteases are produced to degrade the ECM and the 
basement membrane [96-98], 2) endothelial cells (ECs) proliferate and migrate to the 
perivascular area, 3) and form tube-like structures in monolayer from primary 
sprouts, 4) new basement membrane is produced, and 5) pericytes or smooth muscle 
cells are recruited to the surface of the endothelium supporting vessel maturation and 
preventing vascular leakage by covering the vessels leading to stabilized blood vessels 
[92, 95, 99]. Pericytes are recruited to the area by PDGF-B secreted by ECs. Another 
factor required for the maturation process is angiotensin 1 (Ang1) which can activate 
Tie2 receptor on ECs and activate AKT pathway, leading to survival in ECs [100]. 
VE-cadherin, among other adhesion molecules, is an important protein involved in 
supporting the cell junctions between ECs and decreasing vascular permeability by 
binding to each other on neighboring ECs [101].   
Under normal conditions, angiogenesis is a tightly regulated process with several 
growth factors involved [99]. Growth factors including VEGF, stimulate ECs and lead 
to their migration. ECs located in the beginning of the vessels are called tip cells. They 
are invasive and can initiate sprouting, whereas following stalk cells support the 
structure and function of the newly built vessels and are mainly regulated by the Notch 
pathway. VEGF secretion activates VEGFR 2 and Neuropilin 1 (NRP1), which in turn 
increase the expression of the Notch ligand Delta-like 4 (Dll4) [102]. Upon binding to 
its receptor on ECs, Dll4 leads to the release of the intracellular domain of Notch1. This 
domain acts as a transcription factor and controls the VEGF signaling by inhibiting the 
gene expression involved in VEGF responses, such as VEGFR2 and 3, and NRP1 [103, 
104]. VEGFR1 on the other hand, is increased in response to Notch1 signaling. Even 
though VEGFR1 has stronger affinity to VEGF, it has weaker kinase activity. Therefore, 
it can bind VEGF and reduce its activity through VEGFR2 [105]. Another ligand of 
Notch1 is JAGGED1 (JAG1) expressed on stalk cells, negatively regulating Dll4-Notch1 




Figure 7. Normal angiogenesis and its stages. A-D) blood vessels destabilization, 
detachment of pericytes from basal membrane and ECM degradation, EC stimulation by 
growth factors (e.g. VEGF), lumen formation, blood vessel maturation by pericyte 
recruitment. Figure adapted from [92]. 
 
 
1.5.2 Tumor-induced angiogenesis 
 
Tumor cells are highly proliferative host-derived cells that have lost the capacity to 
regulate growth. Although there are many differences between a normal and a tumor 
cell, some of the characteristics are similar. One of these characteristics is the need for 
a sufficient oxygen and nutrient supply and effective ways to eliminate waste in order 
to maintain survival. In order to support their growth, they need to develop new blood 
vessels very fast. To satisfy these demands, tumor cells can induce oxygen and nutrient 
supply from the preexisting vessels in a similar way to normal angiogenesis [107].  
However, these vessels are most of the time immature and lack functionality observed 
in normal tissue [108]. VEGF, transforming growth factor (TGF-β), angiopoietins, 
PDGF-B and other protein families have been associated with imperfect vessels in 
tumors [109]. The improper vessels without pericyte coverage can lead to several 
consequences, such as hypoxia, increased metastasis and decreased activity of 
immune cells [99, 108]. Compared to healthy tissue vasculature, the tumor vessels are 
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twisted, enlarged, damaged, leaky and disordered, which all in turn lead to hypoxia 
and increased permeability. The walls of these vessels can consist of both ECs and 
tumor cells [110]. The connection between pericytes and ECs are compromised due to 
degraded VE-cadherin and therefore the regulation of the vessel permeability is 
impaired [101]. Another important element of blood vessels is the basal membrane. 
There are differences in basal membrane structure between healthy and tumor 
associated vasculature regarding the coverage by smooth muscle actin (SMA), CD31 
and type IV collagen. Other structural irregularities include uneven vessel thickness 
and punctures [92, 111]. Even though the vessels show many abnormalities, they are 
still able to support tumor cells using mechanisms and molecules involved in normal 
angiogenesis [112].  
 
1.5.2.1 Tumor vasculature 
 
Surrounding healthy tissue compresses tumor cells growing uncontrollably which 
leads to suppression of tumor vessels. In addition, decreased perfusion due to leaky 
vessels causes increased pressure in the interstitial space. These events also decrease 
the supply of nutrients and oxygen to tumor cells subsequently leading to hypoxic 
tumors and resistance [113]. As mentioned above, one of the main regulators of 
angiogenesis in tumors is hypoxia. When oxygen is present, hypoxia inducible factors 
(HIFs) are hydrolyzed by prolyl hydroxylase domain protein 2 (PHD2), ubiquitylated 
by Von Hippel–Lindau (VHL) complex and degraded by the proteasome [92, 114]. 
During hypoxia however, PHD2 is inactive, which leads to HIF1-α stabilization and 
binding to hypoxia response elements (HREs) of the target genes such as VEGF, 
glucose transporter type -1 (GLUT-1) and TGF-β [115, 116]. In addition, hypoxia causes 
activation of oncogenes and increases the metastatic ability of tumor cells by 
supporting epithelial to mesenchymal transition (EMT) [92].   
In order to build a vascular network, tumor cells use either sprouting or 
intussusceptive angiogenesis [117]. However, there is an advantage of intussusceptive 
angiogenesis: vessel formation is faster with lower metabolic requirements [118]. 
Intussusceptive angiogenesis occurs through formation of new bridges from 
preexisting vessels and is performed in following steps: 1) using collagen bundles, ECs 
bind to each other and build bridges in the lumen, 2) these collagen bundles migrate 
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into the lumen through degraded basal membrane, 3) a bridge is formed by connection 
of collagen bundles to the of the lumen, 4) the bridge matures by recruiting mural cells, 
such as pericytes [92].  
 
Chaotic, leaky and tortuous tumor vasculature has negative effects on various cancer 
therapies. For example, in presence of oxygen, radiotherapy causes the generation of 
reactive oxygen species (ROS), DNA damage and subsequently cell death [119]. Thus, 
the hypoxic areas of the tumor are less sensitive to irradiation [120]. Additionally, 
hypoxia can also interfere with the delivery and effect of chemotherapeutic drugs. Due 
to collapsed vessel, various drugs might not reach all areas in the tumor and therefore 
have reduced effect [113] as many agents, such as doxorubicin need oxygen to 
effectively lead to cell death [92].  
Decreased perfusion is also reducing the efficiency of brachytherapy where tumors are 
irradiated by using a 188-Rhenium labeled antibody [121]. These antibodies require 
oxygen and an even distribution for their action. The similar reduction in therapy 
effect is also observed with immunotherapies where immune cells have difficulties to 
reach the tumor because of immature blood vessels [122].  
Oxygen level, which can be sensed by different types of cells, is an important regulator 
of angiogenesis [123]. Solid tumors have a necrotic region in the center because of low 
oxygen level [99]. The family of HIF-related transcription factors plays a central role 
in controlling the cellular responses to changes in oxygen level. The three isoforms of 
HIF-α (HIF-1–3), which are only stabilized during hypoxia, can heterodimerize with 
the constantly expressed HIF-1β and induce the expression of several genes [124]. 
Oxygen is not only used by healthy cells, but also by tumor cells in order to survive, 
grow and metastasize. During their growth, tumor cells activate ECs by releasing 
various proteins, such as epidermal growth factor (EGF), fibroblast growth factor 
(FGF), interleukin-8 (IL-8), VEGF and others [98, 125]. Therefore, targeting only one 
of these factors is not sufficient to achieve an effective treatment and a combination of 
pharmacological agents targeting several factors is of great importance. 
Indeed, hypoxia and insufficient vascularization in tumors lead to resistance to 
different types of damages given by different treatment regimens. As an example, 
VEGF mRNA levels were increased in hypoxic areas of glioblastoma, whereas vessels 
were found in close proximity of VEGF producing cells. The leaky vessels in turn lead 
to increased hypoxia and subsequently increased VEGF secretion and continuation of 
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the vicious cycle. One of the most clinically important features of a tumor is its 
capability to metastasize to other organs by taking advantage of increased vessel 
permeability. In this case, VEGF can promote the formation of the leaky vessels, which 
then can be infiltrated by tumor cells. However, there are other factors that can also 
induce new vessel formation in tumors [99, 126, 127].  
 
Figure 8. Tumor vasculature. A and B) immature vessels with decreased coverage by 
mural cells results in insufficient permeability leading to reduced perfusion and increased 
hypoxia. Some areas of the tumor are not sufficiently vascularized due to vessel collapse and 
therefore drugs cannot reach to the whole tumor. Figure adapted from [92]. 
 
1.5.3 Vascular endothelial factor (VEGF) 
 
Among the angiogenic factors, VEGF is probably the most well-characterized. Through 
alternative splicing, six isoforms (121, 145, 165, 183, 189, and 206 amino acids) are 
generated from a single gene. Even though all isoforms demonstrate identical 
biological activities, VEGF165 is the most commonly expressed isoform [128]. VEGF 
is a dimeric glycoprotein [129], which is expressed by different tissues in low levels, is 
highly produced during angiogenesis as well as in majority of human tumors. VEGF 
binds to three known tyrosine kinase receptors: Flt-1 (VEGFR-1) [130], KDR/Flk-1 
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(VEGFR-2) [131], and Flt-4 (VEGFR-3) [132] and can be found on many cell types 
including vascular smooth muscle cells and monocytes/macrophages. It has been 
shown that VEGF mRNA is upregulated in many human cancers (breast, ovary, lung, 
kidney carcinomas, glioblastomas) and many cell lines secrete VEGF as demonstrated 
in in vitro studies [99]. The expression of VEGF and its receptor VEGFR-1 correlate 
with tumor vascularization, increased microvessel density (MVD) and poor prognosis 
for many patients [133, 134]. In addition, tumors can induce VEGF production in 
surrounding tissue, indicating the importance of VEGF for tumor angiogenesis. This 
has been demonstrated by inhibiting VEGF by an anti-VEGF antibody in sarcoma and 
glioblastoma xenografts in nude mice, which lead to reduced vessel density and 
inhibited tumor growth [135]. Similar results have been achieved inhibiting VEGF 
receptor in multiple tumor xenografts (lung, mammary, ovarian carcinomas) [99]. 
Additionally, VEGF can enhance permeability by relaxing junctions between ECs 
through reorganization of cadherin/catenin complexes. By inducing production of 
plasminogen activators (uPA, tPA), plasminogen activator inhibitor-1 (PAI-1) and 
interstitial collagenase, VEGF can stimulate remodeling of ECM components. VEGF 
stimulates EC proliferation and migration in vitro and in vivo [99], inhibits EC 
apoptosis and consequently acts as a survival factor [136]. The production of VEGF is 
also regulated by the availability of oxygen in the tissue [137]. Hypoxia stimulates 
VEGF production through the binding of HIF to the VEGF promoter, and increasing 
VEGF gene transcription and mRNA stability. While this mechanism guarantees that 
developing tissues and hypoxic areas become oxygenated, it also triggers pathological 
conditions (such as cancer) linked with angiogenesis [138].  
VEGF receptors are characterized by seven extracellular immunoglobulin-like 
domains, a transmembrane domain, and a conserved intracellular tyrosine kinase 
domain [139]. VEGFR-1 is expressed in the endothelium as well as in healing skin 
wounds with high affinity for VEGF [99]. Despite its high affinity, VEGFR-1 does not 
mediate proliferation or migration directly. However, VEGFR-2, a tyrosine kinase with 
lower affinity for VEGF, facilitates chemotaxis, mitogenesis and shape alterations of 
ECs [140]. VEGFR-3 is mainly expressed by adult lymphatic endothelium and could 
be involved in lymphangiogenesis and binds VEGF-C and VEGF-D [141].  
NRP1 is another receptor expressed on normal ECs, which binds VEGF165, enables its 
own binding to VEGFR-2, and augments chemotactic effects. VEGF was initially 
identified in tumor cell-conditioned medium as a protein that increased the 
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permeability of blood vessels. It can increase the permeability by improving the 
activity of clustered vesicles in ECs lining the vessels and enable transportation of 











Figure 9. VEGF downstream signaling and its inhibitors. Binding of bevacizumab to 
VEGF inhibits its interaction with the receptors leading to inhibition of downstream signaling. 
Sunitinib and sorafenib, tyrosine kinase inhibitors, are capable of inhibiting different kinases 
of various downstream pathways after VEGF interaction. Figure adapted from [142]. 
 
1.5.4 Placental growth factor (PlGF) 
 
Placental growth factor (PlGF) was first isolated from a term placenta cDNA library in 
1991 as the second member of VEGF-family by Maria Graziella Persico in Napoli, Italy. 
They could identify a 149-amino-acid-long protein with 53% similarity to the platelet 
derived growth factor-like region of VEGF in the amino acid positions 39-132 [143].  
In 1993, it was possible to locate the PlGF gene on chromosome 14q24, containing 
seven exons over 13.7 kb [144]. Due to alternative splicing, PlGF exists in four isoforms 
consisting of 131, 152, 203 and 224 amino acids [144, 145]. PlGF-2 and 4 have a heparin 
binding domain with 21 highly basic amino acids and bind to NRP1 and 2 expressed 
by multiple cells [144, 146-148]. PlGF is an N-glycosylated, homodimeric and secreted 
protein. Each monomer has six cysteine residues that form three intra-chain disulfide 
bonds, creating a cystine-knot motif. Two additional cysteine residues form two inter-
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chain disulfide bonds stabilizing the homodimer. Residues Asp72 and Glu73, and 
glycosylated Asn84 in the N-terminal are important for receptor binding [143, 149-
151]. PIGF is expressed during early embryogenesis and it is highly expressed in the 
placenta during the whole pregnancy regulating the growth and differentiation of 
trophoblasts [144]. Under normal conditions, PlGF expression is low in organs such 
as heart, skeletal muscle and lungs among others [152-154].  
The receptors dimerize and phosphorylate upon ligand binding. PlGF can only bind to 
VEGFR-1 with higher affinity than VEGF-A [145, 155]. Compared to PlGF 
homodimers, PlGF-VEGF heterodimers are approximately up to 50 times less potent 
with regard to receptor binding and activation of downstream signaling pathways [156, 
157]. Specifically, Ig-like domain 2 and 3 of the receptor are important for binding of 
PlGF, hence deletion of domain 3 leads to approximately 500-fold reduction in ligand 
binding [158]. By binding to VEGFR-1, PlGF can displace VEGF-A making it available 
for VEGFR-2, activate a cross-talk between the two receptors and leads to strong 
angiogenic signaling [110]. PlGF can also form a heterodimer with VEGF-A that is able 














Figure 10. Model of PlGF-1 based on crystal structure. Representation of homodimer 
structure of PlGF-1 with disulfide bonds shown in yellow balls (intra-chain) and green balls 
(inter-chain) forming cysteine-knot motif. Each monomer is shown separately in different 




In 1994-1996, the first PlGF expression experiments were performed demonstrating 
higher PlGF expression in renal cell carcinoma compared to surrounding normal 
tissue [160]. Tumor stage, metastasis and survival correlate to PlGF levels in tumors 
[161-163]. However, increased PlGF expression is not observed in all tumors [164].   
In 1997, PlGF was shown to have angiogenic effects in a dose-dependent manner [155]. 
Even though PlGF is highly expressed in the placenta, its deletion did not affect 
embryonic development in mice [110]. Although PlGF deficient mice can develop 
normally, they are unable to adapt to pathological conditions such as inflammation or 
cancer. On the other hand, deletion of PlGF in adults impairs angiogenesis during 
pathological conditions such as tumor growth and ischemia [110, 165].  
Carmeliet and colleagues have shown that PlGF can activate a crosstalk between 
VEGFR-1 and 2 and thereby boosts angiogenesis under pathological conditions [110, 
165, 166]. They could demonstrate that PlGF phosphorylates a distinct tyrosine 
residue and activation of specific downstream pathways and subsequent gene 
expression. This in turn leads to increased VEGF-VEGFR-2 pathway and a separate 
angiogenic signaling [166]. Interestingly, heterodimers of PlGF-VEGF-A inhibit 



















Figure 11. Molecular mechanisms of placental growth factor. A) PlGF binds only to 
VEGFR1 and its soluble version by displacing VEGF-A, making it available for VEGFR2. B) 
PlGF leads to phosphorylation of distinct tyrosine residues on VEGFR1 and stimulates its own 
angiogenic pathway. At the same time, this binding leads to crosstalk activation between the 
two receptor and a stronger angiogenic signaling. Figure adapted from [167].  
 
PlGF can stimulate monocytes to secrete VEGF and increase the expression of IL-1β, 
IL-8 and VEGF [168]. It can recruit macrophages to tumors, wounds and ischemic 
areas [110, 165, 169].  
These macrophages are able to inhibit dendritic cells, NK cells and CTLs leading to 
suppression of antitumor immune response [170]. Moreover, PlGF acts in a synergistic 
way with VEGF and PlGF deficiency correlates with diminished VEGFR-1, which has 
shown to delay wound healing [110]. Loss of PlGF abrogates the macrophage 
polarization and decreases vessel density even in presence of VEGF-A [160].  
In several cancer types, increased PlGF expression correlates with tumor stage, 
metastasis and poor overall survival [167, 171]. Apart from the tumor cells, cells such 
as cancer associated fibroblasts (CAFs), ECs and tumor associated macrophages 
(TAMs) from the surrounding tissue can also express PlGF [110, 164, 165]. 
Consequently, PlGF generates an environment suitable for tumor cells to support their 
growth through different mechanisms, e.g. inducing vessel growth [172-174]. 
Interestingly, blockage of PlGF has shown to normalize vessels in different tumor 
models [174, 175]. On the other hand, a contradictory study shows tumor vessel 
normalization in PlGF overexpressing tumors [176]. According to several other 
studies, PlGF can also be an inhibitor of angiogenesis by creating PlGF/VEGF 
heterodimers when both of the genes are expressed [156, 157, 177]. The potency of the 
heterodimer was shown to be almost 50 times less than homodimers. Proliferation of 
human umbilical vein endothelial cells (HUVECs) in presence of homo- or 
heterodimers showed significantly decreased effect by PlGF/VEGF heterodimers only 
at high concentrations [109, 156, 177, 178]. 
 
Inhibition of VEGF and its receptors leads to increased PlGF levels in patients, 
probably leading to escape and resistance against these therapies [109, 171, 179, 180]. 
Blocking PlGF by RNA interference, neutralizing antibodies or gene silencing has 
shown decreased angiogenesis, tumor growth and metastasis in several mouse models 
[110, 164, 171, 174, 181-183]. Furthermore, a combined therapy with anti-VEGFR2 and 
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anti-PlGF antibodies was more effective than monotherapies. The effect of 
chemotherapy was improved upon PlGF inhibition with subsequent vessel 
normalization [164]. However, not all anti-PlGF antibodies have the same effect on 
tumors, which might partially depend on the expression of VEGFR-1 [175, 184, 185]. 
 
Figure 12. Pleiotropic effects of placental growth factor. As a cytokine, PlGF has 
various effect on survival, proliferation, migration, activation of vascular and nonvascular cells 
and metabolism. Figure adapted from [175].    
 
 
1.5.6 Inhibitors of angiogenesis 
 
1.5.6.1 Endogenous inhibitors 
 
There are more than 40 endogenous inhibitors of angiogenesis which can be divided 
into 4 groups [186]:  
Interferons. Interferons (INF-α, -β and γ) are secreted glycoproteins and have 
antiviral effect [187]. Moreover, IFN-α is able to inhibit tumor-induced migration of 
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ECs in vitro in a dose-dependent manner. In addition, IFN-α and IFN-β can 
downregulate bFGF mRNA and protein levels in several carcinoma cells [188]. 
Interleukins. Interleukins are secreted from leukocytes and have multiple functions, 
including activation and proliferation of lymphocytes [189] and stimulation of B cells 
to secrete IgE. Interleukins, such as IL-8, augments angiogenesis, whereas IL-4 has 
inhibitory effects [190] either by inhibiting tumor cell proliferation, inducing immune 
reaction or blocking EC migration [191].  
Tissue inhibitors of metalloproteinases (TIMPs). It is known that the extracellular 
matrix plays a vital role in angiogenesis [99]. ECs use the components of the ECM, 
which have been modified by metalloproteinases to migrate and form vessels. This 
process is inhibited by TIMPs through their numerous effects on endothelial and 
tumor cells [192]. 
Proteolytic fragments. These fragments are cleaved from large proteins in the ECM 
(collagen, plasminogen, matrix metalloproteinases (MMPs), fibronectin) and possess 
antiangiogenic effects. For example, one of these fragments called angiostatin, a 
fragment of plasminogen, can inhibit the metastases by inhibiting EC growth. 
Fragment of type XVIII collagen called endostatin can inhibit the proliferation of EC 
both in vitro and in vivo [193].  
 
Other antiangiogenic molecules. There are many factors, such as thrombospondin-1 
(TSP-1), that can inhibit tumor angiogenesis, but further investigation is needed to 
characterize these factors. In one study, it was found that high level of TSP-1 was 
secreted only from non-tumorigenic cell line and could inhibit migration of ECs [99].  
 
 
1.5.6.2 Pharmacological inhibitors of angiogenesis 
 
There are several pharmacological inhibitors of angiogenesis that have been approved 
by the Food and Drug Administration (FDA). Anti-angiogenic drugs can lead to 
vascular normalization of tumor blood vessels [113] and improve the delivery of 
chemotherapeutic drugs and radiotherapy [194].  
VEGF has been extensively studied since its involvement in angiogenesis was 
discovered in 1980s [195] and has been targeted to control tumor vessels. One of the 
most recognized agents against VEGF is a humanized anti-VEGF antibody 
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Bevacizumab, which blocks secreted VEGF leading to inhibition of new vessel 
formation and tumor growth [196, 197]. Its effect in combined treatment modalities 
has been investigated in detail. Bevacizumab combined with chemotherapy has shown 
improved survival in gastric cancer, NSCLC and metastatic breast cancer [63, 198, 
199]. However, several side effects (bleeding, hypertension and thromboembolism) of 
the drug were observed when combined with other treatment regimens in different 
cancers, even though combination with carboplatin and paclitaxel showed improved 
overall response  [200-203]. 
In addition to Bevacizumab, agents targeting VEGFRs (e.g. Sunitinib, Sorafenib) have 
also been developed for treatment of cancer treatment [204]. However, the effect of 
these agents depend on tumor type, as prostate and pancreatic cancers do not show 
sensitivity to these treatments [205]. Sunitinib (SU11248) is a tyrosine kinase inhibitor 
(TKI) used for treatment of kidney cancer renal cell carcinoma (RCC) and imatinib-
resistant gastrointestinal tumors. It has also shown favorable results in many cancers 
[98]. Sorafenib (Nexavar) is also a TKI, approved for hepatocellular carcinoma [206], 
advanced renal cell carcinoma [207], and thyroid carcinoma [208] treatment. 
Increased VEGF secretion from tumor cells leads to immature blood vessels. 
Treatment with VEGF inhibitors balances angiogenic processes leading to mature 
vessel network and improved perfusion [209]. Therefore, improvement in the 
combination therapy with VEGF inhibitors and radio/chemotherapy might be due to 
vessel normalization [113]. However, wrong dosage or longer treatments with these 
inhibitors causes regression of the vascular network increasing the risks for metastatic 
disease [210].  
The inhibitors used to treat tumor angiogenesis might also hamper normal angiogenic 
processes, such as blood pressure, reproduction, wound healing and embryonic 
development [211, 212]. For example, one of the prevalent side effects in patients 
treated with inhibitors of VEGF signaling is increased blood pressure. Briefly, VEGF is 
involved in upregulating endothelial nitric oxide synthase (eNOS) and prostacyclin 
(PGI2) in ECs by activating MAPK and PI3K pathways, releasing nitric oxide (NO) and 
resulting in vessel dilation [105, 213, 214]. Consequently, inhibition of VEGF leads to 
decreased NO production, which then induces vessel contraction and elevate blood 
pressure [215]. Inhibition of VEGF can also lead to delays or complications in wound 
healing [216].   
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Apart from their toxicity, a prolonged treatment with VEGF inhibitors show increased 
VEGF-A, -B, -C, PlGF expression, and phosphorylation of their receptors [217]. 
Nevertheless, treatment with anti-angiogenic agents results in a normalized 
vasculature that might allow for better delivery of drugs [98]. 
Radiation on its own induces vessel damage and leads to substantial changes in tumor 
vasculature, blood flow and oxygenation [218]. These changes can be influenced by 
treatment dose, radiation quality and fractionation among others, and are responsible 
for the variances in treatment response. However, using anti-angiogenic drugs results 
in vessel normalization, reduced hypoxia, improved oxygen levels and subsequently 
more effective treatment response when combined with RT [219].  
 
Figure 13. A list of FDA-approved anti-angiogenic drugs that can be used in 
combination with other therapies. Figure adapted from [98].   
 
 
1.5.6.3 Alternative targets  
 
Despite the advantages with VEGF signaling inhibitors, several serious side effects, 
such as hemorrhage and venous thromboembolism can be observed [220]. Another 
severe side effect includes tumor metastasis due to degeneration of normalized tumor 
blood vessels [92]. Lastly, treatment with VEGF inhibitors result in temporary effects 
which can be overcome by resistance mechanisms in tumor cells [179]. Therefore, 
there is an urgent need to find other targets.  
An important modulator of tumor angiogenesis is PDGF-B and its receptors 
PDGFRa/b, closely involved in blood vessel maturation. ECs secrete PDGF-B, which 
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binds to its receptors on pericytes and recruits them to the blood vessels. Combined 
inhibition of PDGFRb with SU6668 and VEGFR with SU5416 demonstrated reduced 
tumor size and improved the effect of radiotherapy [92]. 
Other key players in blood vessels formation are the angiopoietins and Tie2 receptors. 
Angiopoietins bind to Tie2 on ECs leading to their survival, migration and vessel 
formation through receptor phosphorylation and subsequent signaling pathway 
activation [221-223]. Agents targeting the angiopoietin/Tie2 pathways are being 
investigated, where an antibody (MEDI3617) blocking Ang2 shows decrease in lung 
metastasis and tumor associated angiogenesis in several tumor models [224]. 
Moreover, combination therapy with VEGFR and Ang2 inhibitors demonstrated 
improved survival in glioblastoma models [225].  
VE-cadherin is an important regulator of cell-cell junctions between ECs and blood 
vessel permeability. Sac-1004 is a molecule upregulating VE-cadherin through 
activation of the cAMP/Rac/Cortactin pathway and thereby improves the perfusion, 





















2 Aims of Study 
Radiation therapy is an essential treatment method for cancer management. It allows 
precise radiation dose distribution to the tumor while sparing the normal tissue as 
much as possible. In addition to DNA damage and cancer cell killing, radiation therapy 
also leads to secretion of several factors from cancer cells as part of a stress response. 
Our laboratory has been interested in identifying these factors and unraveling ionizing 
radiation induced treatment resistance. One of the factors identified in our large-scale 
secretome analysis was placental growth factor (PlGF), which is known to be involved 
in pathological angiogenesis and is the focus of this PhD thesis. The mechanisms 
behind this IR-induced signal transduction cascade are not fully understood. 
Therefore, in the current PhD project, we aim to investigate these signaling pathways 
and resulting cellular responses more in detail in order to understand the role of PlGF 
as a rescue mechanism to irradiation. 
Based on our results and knowledge, the first part of this project concentrated on the 
characterization of the PlGF response and its regulation in irradiated tumor cells. We 
investigate the expression and secretion of PlGF in response to increasing doses of IR 
in several tumor cell lines with differential genetic backgrounds. In order to determine 
the relevance of signal transduction for IR-induced PlGF-expression, parallel 
experiments in presence of respective small molecular inhibitors are performed. 
Likewise, the expression and secretion of PlGF alone and in combination with 
irradiation under hypoxia is investigated in order to show a differential regulation of 
PlGF. 
The ionizing radiation induced role of PlGF is not fully understood and so far no data 
is available in vitro or in vivo. Therefore, in the second part of the project, we explore 
the role of PlGF as rescue mechanism in response to IR by investigating its paracrine 
effects in vitro using PlGF wildtype or knockout cells. We also investigate the role and 
relevance of PlGF on the tumor vasculature and on the tumor sensitivity to ionizing 
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Background: BAL101553 is a highly soluble prodrug of BAL27862, a novel, small molecule, 
microtubule-depolymerizer inducing tumor cell death through the ‘spindle assembly 
checkpoint’. BAL101553 has anti-cancer activity in diverse tumor models refractory to 
standard therapies, and is currently undergoing Phase 1/2a evaluation in advanced cancer 
patients with IV (weekly) and oral (daily) dosing schedules. Here, the vascular disruption 
activity of BAL101553 was evaluated in the context of administration route and implications 
for combinations with VEGF-targeted therapies.  
Methods: Drug combinations of clinically relevant BAL101553 (MTD i.v. or Oral daily) and 
antiangiogenic agents (Bevacizumab or Everolimus) were investigated in genetically defined 
MTA-resistant lung (A549EpoB40) and colon adenocarcinoma (SW480) tumor xenografts in 
nude mice. We employed endothelial tube formation, and secreted biomarker screening to 
determine the functional relevance of combined treatment. Tumors were analyzed by IHC for 
proliferation (Ki67), tumor hypoxia (Pimonidazole, Carbonic anhydrase-IX) and 
vascularization (CD31, lectin perfusion).   
Results: Sub-cytotoxic BAL27862 concentrations exerted a broad-spectrum inhibitory activity 
on HIF1α protein levels and HIF1α-controlled secretome in vitro and in vivo. Interestingly, 
secretome derived from BAL27862-treated tumor cells diminished endothelial tube formation, 
which could be partially rescued by exogenous VEGF, indicating direct interference of the drug 
on hypoxic adaptation and endothelial tube formation. SW480- or A549EpoB40-derived tumor 
xenografts received once (i.v. 25 mg/kg; high Cmax regimen) or daily (oral 25 mg/kg; low 
Cmax, high AUC) BAL101553 regimens which elicited partial anti-proliferative and 
antivascular effects. Based on these data, combination of the anti-VEGF antibody bevacizumab 
with BAL101553 was assessed in the paclitaxel refractory SW480 and the epothilone resistant 
A549EpoB40 tumor models, using MTD BAL101553 dosing (i.v. weekly & oral daily). All 
monotherapies induced an anti-tumor response. However, bevacizumab combined with IV or 
oral BAL101553 was superior to single agents with the IV combination associated with the 
least functional tumor vasculature.  
Conclusions: BAL101553 targets tumor cell proliferation, tumor hypoxic adaptation and 
vascularization. The latter is Cmax-driven and can be attenuated by daily oral dosing, providing 
an alternative pharmacodynamic endpoint with implications for clinical treatment strategies. 
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IV and orally administered BAL101553 both elicit superior anti-tumor responses in 
combination with anti-VEGF therapy.   
   




Microtubule targeting agents (MTA) are a mainstay in cancer treatment with a curative intent 
or aim to palliate symptoms and to prolong life. The clinical utility of MTAs is often limited 
by MTA-related toxicities and resistance to treatment; the latter is associated with β-
tubulinrelated mutations, overexpression of P-glycoprotein, and altered cellular β-tubulin 
isotype composition [1]. Thus, discovery of novel MTAs alone and in combination with other 
clinically relevant treatment modalities are of high demand to overcome intrinsic or acquired 
resistance mechanisms.   
Therapeutic response and clinical outcome are not solely determined by genetic alterations and 
acquisition of mutations in the neoplastic cells, but also by the fitness advantage conferred by 
the given tumor microenvironment [2]. Tumor cells are the primary targets for classic 
chemotherapeutic treatment. Besides their direct tumor-cell directed cytotoxicity, MTAs are 
also antiangiogenic and show antivascular activity. We and others previously demonstrated 
that MTAs downregulate the HIF-transcriptome and interfere with the secretion of multiple 
tumor cell-derived factors, e.g. vascular endothelial growth factor VEGF and stress-induced 
lysyl oxidase LOX [3, 4]. Thus, the tumor growth-inhibitory effect of MTAs in MTA-sensitive 
tumors might at least in part be due to their indirect, tumor cell-mediated effect on the tumor 
microenvironment [5].  
BAL101553 is a highly soluble prodrug of BAL27862, a novel, small molecule, 
microtubuledepolymerizer inducing tumor cell death through the ‘spindle assembly 
checkpoint’. BAL27862 binds the colchicine site of tubulin with distinct effects on microtubule 
organization, resulting in tumor cell death [6]. BAL101553 has anti-cancer activity in diverse 
tumor models refractory to standard therapies, and is currently undergoing Phase 1/2a 
evaluation in advanced cancer patients with i.v. (weekly) and oral (daily) dosing schedules [7, 
8]. Here, we study the anti-tumor activity and vascular disruption property of BAL101553 in 
the context of administration route and implications for combinations with VEGF-targeted 
therapies.  
Materials and Methods  
Cell culture and Compounds  
SW480 human colon adenocarcinoma, A549 and A549EpoB40 human lung cancer cells were 
cultured in RPMI1640 media supplemented with 10 % (v/v) fetal calf serum, 1 % (v/v) 
penicillin-streptomycin and 1 % (v/v) L-glutamine at 37°C in 5 % CO2. A549EpoB40 cells 
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were maintained in the presence of 10 nM epothilone B. BAL27862 and BAL101553 were 
provided by Basilea Pharmaceutica International Ltd (Basel, Switzerland). BAL27862 (10 mM 
stock) is used for in vitro experiments and is the active moiety of the lysine prodrug 
BAL101553.  
Western blotting  
For western blot analysis, A549, A549EpoB40 and SW480 cells were preincubated with 
BAL27862 (24 h) or RAD001 (1 h) followed by additional incubation for 6 hours under 
normoxic or hypoxic conditions. BAL27862- and RAD001 (Everolimus)-treated tumor cell 
lysates were tested against HIF1α subunit (Santa Cruz Inc., #sc-10790) and anti-β-actin 
antibody (Sigma Aldrich, #A5441) by western blotting. Antibody detection was achieved by 
enhanced chemoluminescence (Amersham, Piscataway, NJ) according to the protocol of the 
manufacturer.  
Bioplex Biomarker Assay and ELISA  
Tumor cells were preincubated with BAL27862 (24 h) followed by additional incubation for 
24 h under normoxic or hypoxic (0.2%) conditions. Customized Bioplex Biomarker Cancer 
Panel assay (17 biomarkers) was performed with undiluted conditioned medium samples 
according to the manufacturer protocol (Bio-Rad). The concentration of VEGF levels in the 
filtered, conditioned media of A549EpoB40 cells was determined using the Quantikine® 
Human VEGF Immunoassay kit (R&D Systems GmbH).   
Endothelial tube formation assay  
The endothelial tube formation assay was performed on the µ-Slide Angiogenesis platform 
according to the protocol provided by the manufacturer (ibidi, #81506). 10 µL of Matrigel (BD 
Basement Membrane Matrix, #354234) was loaded in each well of the 15-well µ-Slide and 
HUVECs were plated at the appropriate cell density (10,000 cells/well). Capillary-like tube 
formation was observed after 16 h using a microscope (Axiovert 40 CFL, Zeiss with Axiocam) 
and quantified using Angiogenesis Analyzer from ImageJ (NIH). Original images (5 images 
per treatment group) were transformed to binary images and further skeletonized to compute 
parameters such as number of segments (Nb segments) and meshes (Nb mesh) using 





Tumor xenografts  
Tumor xenografts derived from A549EpoB40 and SW480 cells in athymic nude mice were 
generated as described in [9] and allowed to expand to a volume of 200 mm3 (±10%). 
BAL101553 (dissolved in buffered saline) was applied as either a bolus (i.v. 21.3 mg/kg, once 
a week over three weeks) or daily p.o. (oral 15 mg/kg, 5 days/week over three weeks). 
Bevacizumab (Avastin, Roche, concentrated infusion solution) was diluted with saline and 
injected i.p. at 5 mg/kg twice on day 1 and day 4 (in both SW480 and A549EpoB40 xenografts). 
Control mice received a corresponding placebo-treatment (buffered saline). This study was 
performed in strict accordance with the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the Swiss Cantonal Veterinary Authorities.  
Immunohistology   
Immunohistological endpoints were analyzed on formalin fixed and paraffin embedded blocks 
for Ki-67 (prediluted; Ventana-Roche, 790-4286), CD31 (1:10; Dako, M0823), IL8 (1:20; 
R&D Systems, MAB330), Pimonidazole (1:100; Hypoxyprobe, HP1-1000), and Carbonic 
anhydrase (1:6000; Abcam, ab15086) using a Discovery Immunohistochemistry Staining 
System (Ventana Medical Systems). Ki-67–positive tumor cells and amount of vessels (CD31) 
were counted in at least four randomly chosen visual fields (magnification, 400X) in each 
xenograft (n=4 for each group). Mice were injected with FITC_Agglutinin (i.v. 100 µg/mouse) 
1 hour before tumor harvesting and % of functional perfused vessels were calculated as ratio 
of Agglutinin+CD31+ vessels to total CD31+ vessels. Whole tumor sections were quantified 
for specific H&E, Pimonidazole or CA-IX staining intensity employing a 2000 µm manual 
counting grid (n=4 for each treatment group).  
Statistical analysis  
Statistical analyses were performed using GraphPad Prism (version 5). If not indicated 
otherwise, in vitro data were analyzed using the unpaired Student t test and data represent at 
least three independently performed assays. In vivo treatment response was evaluated by two 
different statistical metrics. Areas under the tumor volume curve (AUC) were analyzed by 
oneway ANOVA using the Tukey Test for pair-wise comparisons. Additionally, tumor growth 
delays were also calculated by Kaplan Meier analysis with Log-rank (Mantel-Cox) test for 
pairwise comparisons. Immunohistochemical data were analyzed by one-way ANOVA on 
replicate tumor samples (n=4) and pair-wise analysis was performed using the Tukey Test. For 




BAL27862 decreases HIF1α levels and subsequent downstream VEGF-expression and 
secretion  
Our previous work demonstrated that the tumor growth-inhibitory effect of MTAs in 
MTAsensitive tumors might at least in part be due to downregulation of the HIF-transcriptome 
thereby contributing to an indirect, tumor cell-mediated effect on the tumor microenvironment 
[4, 5] To probe for its HIF-repressive capacity, the novel microtubule-destabilizing agent 
BAL27862 was tested for its HIF-interfering capacity in MTA-resistant colon and NSCLC 
tumor cell lines.  
Parental A549, PgP-overexpressing paclitaxel-resistant SW480 and epothilone resistant 
(βtubulin mutated) A549EpoB40 cells were preincubated with BAL27862 (24 h) followed by 
6 h incubation under normoxic or hypoxic (0.2% oxygen) conditions (IC50s: 28 nM, 9 nM & 
22 nM, respectively; [10]). Western blot analysis of whole cell lysates revealed potent 
downregulation of HIF1฀ levels after BAL27862 treatment in all the three cell lines (Figure 
1A). Additionally, VEGF secretion was significantly upregulated under hypoxia, but not in 
cells pretreated with subtoxic concentrations of BAL27862 (10 nM, Figure 1B). These results 
indicate that an intact microtubular network is required for HIF1α stabilization under hypoxia 
and subsequent VEGF-secretion. Cellular preincubation with the microtubule-destabilizing 
agent BAL27862 is sufficient to interfere with HIF1α stabilization, presumably through 
deregulated HIF1α -expression.  
BAL27862 exerts a broad-spectrum inhibitory activity on HIF1α-controlled secretome 
in vitro and in vivo  
We previously identified that MTAs indirectly affect the tumor microenvironment via 
regulation of tumor cell-derived secretory factors [5]. Secreted factors are key mediators of 
cellcell communications and their altered levels enable tumor progression and therapy 
resistance [3, 11, 12]. Therefore, Bioplex-based exploratory analysis was performed to assess 
secretion status of 17 key cancer biomarkers in response to subtoxic levels of BAL27862 (10 
nM) in SW480 and A549EpoB40 tumor cells under both normoxic and hypoxic (0.2%) 
conditions. Interestingly, BAL27862 exerted a broad-spectrum inhibitory activity on the 
HIF1α-controlled secretome resulting in reduced secreted levels of HIF1α-downstream factors 
such as VEGF, IL8, OPN (Osteopontin), SCF (Stem cell factor), and PAI-1 (Plasminogen 
activator inhibitor1) (Figure 2A and 2B). Similar HIF1α-downstream inhibitory activity could 
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also be determined in the SW480 cells with increased concentration of BAL27862 (20nM, 
Supplementary Figure 1A).  
To confirm our findings in vivo, we developed tumor xenografts derived from taxane-resistant 
SW480 and patupilone-resistant A549EpoB40 tumor cells and treated mice with either a bolus 
(i.v. 21.3 mg/kg, day 1) or a daily p.o. (oral 15 mg/kg, day 1 - 5) regimen of BAL101553. 
Tumors and blood sera were harvested on day 7 after treatment. Ex vivo analysis of blood 
serum from BAL101553-treated SW480- and A549EpoB40-derived tumor xenografts revealed 
significantly reduced levels of IL8 in comparison to blood serum levels from vehicle-treated 
mice (Figure 2C and 2D). Unfortunately, VEGF concentrations were below a minimal 
technically detectable concentration.  
Additionally, we also observed reduced immunohistochemical staining of IL8 in tumor 
sections derived from BAL101553-treated xenografts in comparison to vehicle-treated tumors 
(Figure 2E and 2F).  Of note, TNFα (Tumor necrosis factor alpha), a hypoxia independent 
marker did not change in response to this novel MTA indicating specific HIF1α-mediated 
inhibitory activity of BAL27862 and BAL101553 in vitro and in vivo, respectively, 
(Supplementary Figure 1B and 1C).   
These results demonstrate that BAL27862 exerts a broad-spectrum inhibitory activity on the 
HIF1α-controlled secretome across a panel of MTA-resistant cell lines and tumor xenografts.  
 The secretome of BAL27862-treated tumor cells diminishes endothelial tube formation, 
which can be partially rescued by exogenous VEGF  
The role of a deregulated HIF1α-downstream secretome was studied in vitro by investigating 
tube formation in HUVECs. The secretome (conditioned medium) derived from 
BAL27862treated A549 cells diminished capillary-tube formation and vascular organization 
of HUVEC cells in a paracrine manner mimicking a phenotype similar to direct treatment of 
HUVECs with the anti-VEGF targeting antibody bevacizumab (Figure 3A). The inhibition of 
endothelial tube formation could be partially rescued by exogenous addition of VEGF 
suggesting that the VEGF signaling pathway is partially required for tube formation in this 





Modest proliferation and mean vessel density decrease in SW480 and A549EpoB40 
tumors after short-term i.v. and oral BAL101553 treatment  
Our own pharmacokinetic and pharmacodynamic experiments performed in preclinical tumor 
models with BAL101553 alone revealed two near-equipotent treatment regimens of 
BAL101553 [i.v. once (21.3 mg/kg) and oral daily (5 x 15 mg/kg)], with increased tolerability 
with the oral route [7, 10]. Equivalent and statistically significant reductions in the proliferation 
indices (Ki-67) and mean vessel density (CD31) were observed in both the treatment groups 
after BAL101553 treatment in both SW480- and A549EpoB40-derived tumor xenografts 
(Figure 4A and 4B). However, determination of treatment-related body weight changes 
revealed a considerable BAL101553-dependent transient weight loss over 48 h after i.v. bolus 
but not during the oral daily regimen indicating lesser toxicity and better tolerability with the 
oral regimen in these tumor models (Suppl. Figure 2A and 2B).  
Although single BAL101553 treatment in these tumor models display clear anti-tumor and 
antivascular activity, we speculated that combining BAL101553 with an antiangiogenic agent 
could drastically improve treatment response and outcome while effectively managing any 
additive or synergistic toxicities.  
Combination of i.v. or oral BAL101553 with bevacizumab in MTA-resistant tumor 
xenografts  
To assess the anti-tumor efficacy of BAL101553 with its indirect anti-vascular activity in 
combination with direct anti-angiogenic targeting, the combination of the anti-VEGF antibody 
bevacizumab with BAL101553 was assessed in the paclitaxel refractory SW480 and the 
epothilone resistant (β-tubulin mutated) A549EpoB40 tumor model, using equipotent MTD 
BAL101553 dosing (i.v. weekly & oral daily). In the taxane-resistant SW480 tumor model, all 
monotherapies induced an anti-tumor response (ΔT/Cs bevacizumab: 35%; i.v. BAL101553: 
22%; oral BAL101553: 53%). However, bevacizumab combined with i.v. or oral BAL101553 
was superior to either of the single agents (ΔT/C: 6% and 17%, resp.) (Figure 5A). Furthermore, 
the absolute growth delay to triple the initial tumor volume (200 mm3) was most enhanced in 
response to the combined treatment modality when compared with the absolute tumor growth 
delay in response to i.v. or oral BAL101553 or bevacizumab alone (P < 0.01 for i.v. or oral 
BAL101553 plus bevacizumab versus vehicle and each monotherapy), respectively, suggesting 
a positive interaction between BAL101553 and bevacizumab (Suppl. Figure 3A).  
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While SW480 cells overexpress the multidrug resistance (MDR)–related efflux pump 
Pglycoprotein, thereby strongly reducing the potency of P-glycoprotein substrates such as 
taxanes, many tumors carry a specific mutation in the MTA binding region of β-tubulin, leading 
to epothilone and taxane resistance. We probed the strategy to combine BAL101553 with 
bevacizumab also in the defined β-tubulin mutated carcinoma tumor model (A549EpoB40). In 
the A549EpoB40 tumor model, all monotherapies induced an anti-tumor response (ΔT/Cs 
bevacizumab: 57%; i.v. BAL101553: 49%; oral BAL101553: 57%). However, bevacizumab 
combined with i.v. or oral BAL101553 was superior to either of the single agents (ΔT/C: 9% 
and 22%, resp.) (Figure 5B).  
Downregulation of the HIF-transcriptome with subsequent reduction of tumor-derived VEGF 
expression and secretion could also be executed by the mTOR inhibitor everolimus instead of 
bevacizumab in MTA-resistant tumors. Surprisingly, we did not observe any additive tumor 
growth delay in response to the combination of BAL101553 (i.v. weekly or oral daily) and 
Everolimus (Figure 5C), even though treatment with everolimus, a PgP-substrate, led to 
significant downregulation of phosphorylated P70-S6Kinase in these SW480 tumors (Suppl. 
Figure 3B).  
Determination of treatment-related body weight changes revealed a minor 
BAL101553dependent transient weight loss over 48 hours after i.v. bolus but not during the 
p.o. daily regimen (Suppl. Figure 3C and 3D). Analysis of tissue morphology and integrity of 
skin adjacent to the tumor did not reveal any normal tissue toxicities in response to the 
combined treatment modality (data not shown).  
Induction of tumor necrosis, reduced proliferation and enhanced anti-vascular effects 
with BAL101553/bevacizumab combinations in MTA-resistant tumor xenografts  
To determine the anti-vascular effect of the different treatment modalities in situ, microvessel 
density (CD31) and perfusion (agglutinin perfusion), necrosis (H&E), proliferation (Ki67) and 
tumor hypoxia (Pimonidazole and carbonic anhydrase) were determined in tumor sections 
(Figures 6, 7). Interestingly, tumor necrosis was dramatically increased in both combination 
groups (BAL101553 administered i.v. weekly or oral daily with bevacizumab) as compared to 
the single agents in both tumor models (SW480, Figure 6, 7A; A549EpoB40 Figure 7D and 
Supplementary Figure 4A).   
Moreover, reductions in proliferation and mean vessel density within viable areas of the tumor 
were also observed in the combination groups (SW480, Figure 6, 7B; A549EpoB40 Figure 7E 
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and Supplementary Figure 4). Strikingly, i.v. BAL101553 in combination with bevacizumab 
was associated with the least functional tumor vasculature (based also on vascular perfusion 
experiments) whereas the daily-oral BAL101553 regimen had the least anti-vascular activity, 
despite imparting similar anti-tumor activity in combination (Figure 7C and 7F).  
IL8 (CXCL8) as a novel predictive circulating biomarker for efficacy of combined 
BAL101553 and Bevacizumab regimen  
Secreted serum components can be associated with treatment efficacy and could potentially 
participate in the generation of de novo resistance mechanisms. We performed analysis of 
blood serum derived from SW480 and A549EpoB40 tumor xenografts. Tumors and blood sera 
were harvested on day 7 after treatment with either bolus BAL101553 (i.v. 21.3 mg/kg, day 1) 
or daily BAL101553 (oral 15 mg/kg, day 1 - 5) and Bevacizumab (i.p. 5 mg/kg, day 1 and 4). 
Ex vivo analysis of blood serum from BAL101553-treated SW480- and A549EpoB40-derived 
tumor xenografts revealed significantly reduced levels of IL8 in comparison to blood serum 
levels from vehicle-treated mice. Importantly, combined treatment with BAL101553 (i.v. or 
oral daily) and bevacizumab also led to significantly reduced serum levels of IL8 in the blood 
serum of mice in comparison to bevacizumab or vehicle-treated tumors (Figure 7G and 7I). 
Additionally, we also observed reduced immunohistochemical staining of IL8 in tumor 
sections derived from combined BAL101553 and bevacizumab-treated xenografts in 
comparison to monotherapy or vehicle-treated tumors (Figure 7H and Supplementary Figure 
5). These results suggest that post-treatment IL8 serum levels may be associated with the 
efficacy of BAL101553 and bevacizumab-containing regimen.  
 
Discussion  
Therapy resistance invariably limits the clinical efficacy of microtubule targeting agents 
against advanced metastatic cancers. Influence of chemotherapeutic resistance, whether 
intrinsic or acquired is drastic as it causes treatment failure in over 90% of patients with 
metastatic cancer and can hamper the effectiveness of the therapy even in the adjuvant setting 
[13]. Antiangiogenic tumor therapies, especially targeting the VEGF pathway, have shown 
statistically significant and clinically meaningful improvement in survival among metastatic 
advanced non-small cell lung and colorectal cancer patients [14, 15].  
We previously identified that bevacizumab in combination with epothilone or taxane can 
overcome MTA-resistance in otherwise MTA-refractory tumor models [5]. We have here 
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demonstrated the potency of the combined treatment modality of novel the MTA BAL101553 
with bevacizumab, that is active both in taxane-resistant and β-tubulin-mutation-linked 
epothilone-resistant tumor cells [7, 8].   
BAL101553 is a small molecule tumor checkpoint controller, currently in clinical phase 1/2a 
evaluation in patients with advanced solid tumors or glioblastoma (brain cancer). BAL101553 
binds to tubulin at a site not targeted by any approved microtubule-targeting agent and 
demonstrates efficacy against diverse treatment-resistant cancer models, including tumors 
refractory to conventional approved therapeutics and radiotherapy [6-8].  
Due to its intravenous and oral bioavailability, different dosing regimens for BAL101553 are 
being assessed (Trial IDs: NCT01397929, NCT02895360, NCT02490800). While the i.v. 
bolus regimen might be more directly cytotoxic and antivascular, the daily-oral route 
application might induce a pseudo-metronomic effect. Of note, currently approved MTAs 
cannot be administered clinically with a daily oral schedule.   
Serum circulating cytokines and angiogenesis-related secreted factors are hypothesized to be 
valid biomarkers for the angiogenic and hypoxic status of the tumor microenvironment and 
may offer prognostic and predictive information beyond conventional clinico-pathological 
indicators [16]. Based on an explorative secretome screening, we identified that post-treatment 
IL8 serum levels may be associated with the efficacy of BAL101553 and 
bevacizumabcontaining regimens.  
Overall, our results clearly demonstrate that BAL101553 targets tumor cell proliferation, tumor 
hypoxic adaptation and vascularization. IV and oral administration of BAL101553 provides an 
alternative pharmacodynamic endpoint with implications for clinical combined treatment 
strategies with anti-VEGF therapies.  
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Figure Legends  
Figure 1. BAL27862 inhibits HIF1α levels and subsequent downstream VEGF-expression 
and secretion. (A) BAL27862- and RAD001-treated A549, A549EpoB40 and SW480 cell 
lysates were tested with an anti-HIF1α subunit antibody by western blotting. Cells were 
preincubated with BAL27862 (24 h) or RAD001 (1 h) followed by additional incubation for 6 
hours under normoxic or hypoxic conditions. (B) Regulation of VEGF secretion by BAL27862. 
Tumor cells were treated with BAL27862 (10 nM, 24 h) and cultured under normoxic and 
hypoxic (0.2%). Supernatants were collected 24 hours after starting hypoxic conditions and 
analyzed for VEGF protein levels by ELISA. Unpaired Student t test, data are represented as 
mean ± SD. *, P <0.05.  
 
Figure 2. BAL27862 exerts a broad spectrum inhibitory activity on HIF1α-controlled 
secretome. Cancer biomarker screening was performed with Bioplex multiplex technology 
against conditioned media (CM) derived from untreated and BAL27862-treated SW480 colon 
carcinoma (A) and A549EpoB40 lung adenocarcinoma (B) cells. Cells were preincubated with 
BAL27862 (24 h) followed by additional incubation for 24 hours under normoxic or hypoxic 
(0.2%) conditions. (C-D) Serum levels of IL8 in murine blood derived from i.v. BAL101553 
(21.3 mg/kg, day 1), oral BAL101553 (15 mg/kg, day 1 - 5) or vehicle-treated SW480- and 
A549EpoB40-derived tumor xenografts. Tumors and blood sera were collected 7 days after 
treatment start. (E-F) Representative images and quantification of immunohistochemical 
staining intensity for IL8 in tumor sections derived from SW480- and A549EpoB40 tumor 
xenografts (n=4). Viable tumor sections were evaluated for specific IL8-staining intensity. 
Scale bar 100 μm. One-way ANOVA, data are represented as mean ± standard deviation. 
*P<0.05.  
 
Figure 3. The secretome of BAL27862-treated tumor cells diminishes endothelial tube 
formation, which can be partially rescued by exogenous VEGF. A549 cells were pretreated 
with different indicated concentrations of BAL27862 (0 nM, 5 nM or 20 nM) for 24 hours and 
then replated in fresh EGM media for 16 hours for conditioning. Naïve HUVEC cells were 
treated with either VEGF (100 ng/ml), bevacizumab (50 µg/ml) or with conditioned media 
(CM) collected as explained above. The formation of capillary-like networks was acquired after 
12 hours by inverted microscopy (5 replicates per group) and analyzed using the Angiogenesis 
Analyzer ImageJ toolkit. (A) Number of meshes and segments of the HUVEC-tubes after 
treatment as described above. (B-C) Representative images and quantification of the HUVEC 
tube formation in response to conditioned media (CM) derived from untreated- and BAL27862-
treated (20 nM) A549 cells, with and without exogenous addition of VEGF (100 ng/ml). 
Unpaired Student t test, data are represented as mean ± SD. *, P < 0.05. 
  
Figure 4. Partial proliferation and mean vessel density decrease in SW480 and 
A549EpoB40 tumors after short-term BAL101553 treatment. (A) SW480- or (B) 
A549EpoB40-derived tumor xenografts (n = 4 per group) were treated with either i.v. 
BAL101553 (21.3 mg/kg, day 1), oral BAL101553 (15 mg/kg, day 1 - 5) or vehicle (buffered 
saline, day 1 - 5), and tumors were collected 7 days post-treatment start. Viable tumor areas 
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were evaluated for necrotic areas (Haematoxylin & Eosin), Ki67, and CD31. Data is 
represented as mean ± SD; one-way ANOVA on replicate tumor samples (n = 4); pair-wise 
analysis using the Tukey test.   
 
Figure 5. Effect of BAL101553 and Bevacizumab alone and in combination on the growth 
of SW480 and A549EpoB40-derived tumor xenografts.  (A) SW480- or (B) A549EpoB40-
derived tumor xenografts were treated with vehicle or BAL101553 (21.3 mg/kg i.v. once a 
week or 15mg/kg p.o. daily, over three weeks) and bevacizumab (5 mg/kg on day 1 and 4 
during first week) alone and in combination. (C) SW480derived tumor xenografts were treated 
with vehicle or BAL101553 (21.3 mg/kg i.v. once a week or 15mg/kg p.o. daily, over three 
weeks) and everolimus (5 mg/kg on day 1 – 5 during first week) alone and in combination. 
Each curve represents the mean tumor volume per group ± SE (n = 7-9), one-way ANOVA 
Tukey test.   
 
Figure 6. Induction of tumor necrosis, reduced proliferation and enhanced anti-vascular 
effects with BAL101553/bevacizumab combinations in SW480 tumor xenografts. SW480-
derived tumor xenografts (n = 4 per group) were treated as described, and tumors were collected 
7 days post-treatment start. Mice were injected with Pimonidazole (IP; 4 μg/gm mouse weight) 
1 h before tumors were harvested, formalin fixed and stained for Haematoxylin and Eosin 
(H&E), Ki67, CD31, Pimonidazole and Carbonic anhydrase. Scale bar: 1 mm (CD31 100 μm; 
50 μm for magnified images).  
Figure 7. Response to treatment with BAL101553 (21.3 mg/kg i.v. weekly or 15 mg/kg p.o. 
daily) and bevacizumab alone and in combination.  (A, D) Necrotic areas (Haematoxylin & 
Eosin) (B, E) Mean vessel density (CD31) (C, F) % of functional perfused vessels (Ratio of 
Lectin+CD31+ vessels to total CD31+ vessels) in (A, B, C) SW480- or (D, E, F) A549EpoB40-
derived tumor xenografts. Data is represented as mean ± SD; one-way ANOVA on replicate 
tumor samples (n = 4); pair-wise analysis using the Tukey test. (G, I) Serum levels of IL8 in 
murine blood derived from (G) SW480- or (I) A549EpoB40tumors treated with either bolus 
BAL101553 (i.v. 21.3 mg/kg, day 1) or daily BAL101553 (oral 15 mg/kg, day 1 - 5) and 
bevacizumab (i.p. 5 mg/kg, day 1 and 4). Tumors and blood sera were collected 7 days after 
treatment start; n = 4. (H) Representative images and quantification of immunohistochemical 
staining intensity for IL8 in tumor sections derived from SW480 tumors (n=4). Viable tumor 
sections were evaluated for specific IL8-staining intensity. Scale bar 100 μm. One-way 
ANOVA, data are represented as mean ± standard deviation. *P<0.05.  
 
Supplementary Figure Legends  
Suppl. Figure 1. BAL27862 exerts a broad spectrum inhibitory activity on 
HIF1αcontrolled secretome. In SW480 colon carcinoma cells, cancer biomarker screening 
was performed with Bioplex multiplex technology against conditioned media derived from 
untreated and BAL27862-treated cells (A). Cells were preincubated with BAL27862 (20nM, 
24 h) followed by additional incubation for 24 hours under normoxic or hypoxic (0.2%) 
conditions. (B) Regulation of TNFα secretion by BAL27862. SW480 and A549EpoB40 cells 
were treated with BAL27862 (10 nM, 24 h) and cultured under normoxic and hypoxic (0.2%). 
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Supernatants were collected 24 hours after starting hypoxic conditions and analyzed for TNF-
α protein levels. (C) Serum levels of TNF-α in murine blood derived from i.v. BAL101553 
(21.3 mg/kg, day 1), oral BAL101553 (15 mg/kg, day 1 - 5)) or vehicle-treated SW480- and 
A549EpoB40-derived tumor xenografts. Tumors and blood sera were collected 7 days after 
treatment start.  
 
Suppl. Figure 2. Body weight determination in response to treatment. Daily body weights 
of mice with SW480- (A) and A549EpoB- (B) derived tumors in response to treatment with 
BAL101553. Each curve represents the mean weight per group ±SEM.  
  
Suppl. Figure 3. Combination of BAL101553 with bevacizumab in MTA-resistant tumor 
xenografts. Kaplan–Meier survival analysis for SW480 tumors reaching 600 mm3 tumor 
volume after treatment with BAL101553 (i.v. weekly or p.o. daily) or bevacizumab or their 
combination; n=7-9, log-rank (Mantel–Cox) test for pair-wise comparisons (A). (B) 
Representative images of immunohistochemical staining intensity for phosphorylated P70-
S6kinase in tumor sections derived from SW480 tumor xenografts. (C, D) Daily body weights 
of mice with SW480- (C) and A549EpoB-(D) derived tumors in response to treatment with 
BAL101553 and bevacizumab. Each curve represents the mean weight per group ±SD.  
 
Suppl. Figure 4. Induction of tumor necrosis, reduced proliferation and enhanced 
antivascular effects with BAL101553/bevacizumab combinations in A549EpoB40 tumor 
xenografts. A549EpoB40-derived tumor xenografts were treated as described and tumors were 
collected 7 days post-treatment start. Mice were injected with Pimonidazole (IP; 4 μg/gm 
mouse weight) 1 h before tumors were harvested, formalin fixed and stained for Haematoxylin 
and Eosin (H&E), Ki67, CD31, Pimonidazole and Carbonic anhydrase. Scale bar: 1 mm (CD31 
100 μm).  
 
Suppl. Figure 5. Immunohistochemical staining of IL8 (CXCL8) in response to combined 
BAL101553 and Bevacizumab regimen in A549EpoB40-derived tumor xenografts. 
Representative images and quantification of immunohistochemical staining intensity for IL8 in 
tumor sections derived from A549EpoB40 tumors (n=4). Viable tumor sections were evaluated 
for specific IL8-staining intensity. Scale bar 100 μm. One-way ANOVA, data are represented 
as mean ± standard deviation. *P<0.05.  
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Purpose: Placental growth factor (PlGF) is a pro-angiogenic, N-glycosylated and 
secreted growth factor. As a stress response to ionizing radiation (IR), tumor cells 
show increased secretion of PlGF. Here, we investigated the regulation of PlGF in 
response to IR and its role for tumor angiogenesis and radiosensitivity.    
Experimental design: Secretion and expression kinetics of PlGF across multiple 
cancer cell lines was determined using ELISA. PlGF regulation was mechanistically 
investigated in D341, DAOY and HCT116 cells. Tumor angiogenesis and 
radiosensitization in PlGF wildtype and PlGF knockout cells were determined in a 
medulloblastoma tumor xenograft model.     
Results: Secretion and expression of PlGF in response to irradiation was investigated 
in multiple tumor cell lines in a dose- and time-dependent manner. IR induced early 
upregulation of PlGF expression in p53 wildtype tumor cells, whereas tumor cells with 
mutated p53 only showed a minimal or delayed response. Mechanistic investigations 
with genetic and pharmacological targeting of p53 corroborated regulation of PlGF by 
the tumor suppressor p53. A paracrine role of PlGF was investigated by exploring 
migration of irradiated HUVECs towards non-irradiated and irradiated PlGF wildtype 
and PlGF knockout medulloblastoma cells and tumor xenografts thereof. Tumors 
derived from PlGF-ko cells displayed a reduced growth rate, but similar tumor 
vasculature formation as their wildtype counterparts. Interestingly though, high-dose 
irradiation strongly reduced microvessel density with a concomitant high rate of 
complete tumor regression only in the PlGF-ko tumors.   
Conclusions: Expression and secretion of PlGF in response to irradiation is strongly 
regulated by transcriptional activity of the tumor suppressor p53. In p53-mutated tumor 
cells though, hypoxia-related factors and other so far unresolved mechanisms strongly 
contribute to a delayed expression of PlGF. Irradiation-induced PlGF plays a strong 
vasculature-protective role thereby contributing to enhanced radiation resistance in 
vivo. These results suggest PlGF to be a relevant target for a combined treatment 






Radiotherapy (RT) is widely used as part of combined treatment modality and is 
considered as one of the most effective treatments for the management of solid 
tumors. In addition to DNA damage and genome instability, ionizing radiation (IR) also 
leads to stress responses in tumor cells by activating signal transduction pathways 
and inducing secretion of several auto- and paracrine factors [1, 2]. IR is usually 
combined with pharmaceutical agents targeting biologically relevant resistance 
mechanisms to achieve local tumor control and improve survival rates [3-7]. We 
recently performed an exhaustive semi quantitative dot blot secretome analysis from 
irradiated tumor cells and identified among others that placental growth factor (PlGF) 
is secreted from tumor cells in response to irradiation. A secondary analysis revealed 
that multiple of these factors, but not PlGF, are substrates of the matrix 
metalloproteinase ADAM17 and that irradiation enhances its sheddase activity in an 
IR-dose-dependent way [8].   
PlGF is an N-glycosylated, homodimeric protein and belongs to the vascular 
endothelial growth factor (VEGF)-family, with 53% similarity to the platelet derived 
growth factor (PDGF)-like region of VEGF [9]. The PlGF gene contains seven exons 
and due to alternative splicing exists in four isoforms consisting of 131, 152, 203 and 
224 amino acids [10, 11].  Under normal conditions, PlGF expression is low in organs 
such as heart, skeletal muscle and lungs [12-14]. Binding of PlGF to its receptor 
vascular endothelial growth factor receptor 1 (VEGFR1) leads to phosphorylation of 
the receptor, activation of downstream pro-angiogenic signaling pathways and a 
crosstalk between VEGFR-1 and 2 [15-18]. Compared to VEGF-A, PlGF is not as 
extensively investigated and its regulation and role in response to irradiation is poorly 
understood. PlGF is highly expressed in the placenta, however, its deletion does not 
affect embryonic development in mice [16]. While PlGF-deficient mice can develop 
normally, they are unable to adapt to pathological conditions such as inflammation or 
cancer [16, 17].   
Several studies demonstrate the contribution of PlGF to tumor angiogenesis under 
pathological conditions. Tumor stage, metastasis and poor overall survival correlate 
to increased PlGF levels in different tumors entities [19-24]. Of note inhibition of VEGF 
and its receptors leads to increased PlGF levels, probably contributing to escape and 
resistance against these treatment modalities [24-27].  On the preclinical level as 
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investigated in several mouse models, blocking of PlGF by RNA interference, 
neutralizing antibodies or gene silencing resulted in decreased angiogenesis, reduced 
tumor growth and dissemination [16, 24, 28-32]. Interestingly, while blockage of PlGF 
normalized tumor vessels in some tumor models [28, 33], tumor vessel normalization 
was also observed in PlGF overexpressing tumors [34].   
Expression of PlGF is regulated by several transcription factors, however contradictory 
results exist on the regulation of PlGF by the tumor suppressor p53 and the 
hypoxiainducible factor HIF-1α [9, 16, 18, 29, 35-37]. Furthermore, almost no data 
exist on the regulation of PlGF in response to irradiation [38]. Here we investigate 
expression and secretion of PlGF across multiple tumor cell lines in response to 
irradiation and in dependence of the tumor suppressor protein p53. Short-time 
efficacy-oriented experiments performed in vivo indicate a vessel-protective role of 
PlGF in response to irradiation.   
  
Materials and methods  
Cell cultures and treatments  
Human lung adenocarcinoma cells (A549, H460, H358, H292, H125) (ATCC) were 
cultured in RPMI1640 media, medulloblastoma cells (D341, D425, DAOY, UW228) 
(kindly provided by Martin Baumgartner, Kinderspital) in improved MEM media  
(Richter’s modification) and head and neck squamous cell carcinoma cells (FaDu) 
(ATCC) in DMEM media. All media were supplemented with 10% (v/v) fetal calf serum, 
1% (v/v) penicillin-streptomycin and 1% (v/v) L-glutamine and cells were kept at 37 °C 
in 5% CO2. All cell culture media and supplements were purchased from Gibco (Life 
Technologies). HUVECs, Endothelial Cell Growth Medium (ECGM) and 
supplementary growth factors were purchased from Promocell. Cells were pretreated 
with Pifithrin-α (S2929, Selleckchem), MI-773 (S7649, Selleckchem), BAY 87-2243 
(S7309, Selleckchem) in given concentrations 1-2 hours prior to irradiation with an 
Xstrahl 200kV X-ray unit at 1Gy/min or RS-2000 225kV irradiator at 4.2Gy/min (Rad 
Source). Hypoxia experiments were performed at 1% O2 after cells were treated with 





Bio-Plex assay  
Bio-Plex (Bio-Rad, 6156 and 6304) is a fluorescently dyed bead-based assay, with 
similar principles to a sandwich ELISA, where each bead has a color code permitting 
detection of different biomarkers in a suspension. Briefly, beads are covalently coupled 
to a capture antibody directed against specific biomarker and are incubated with 
standards or samples (supernatant derived from non-irradiated and irradiated A549 
cells). After a washing step, beads are incubated with biotinylated detection 
antibodies. The unbound biotinylated antibodies are washed and the beads are 
incubated with a fluorescence reporter streptavidin-phycoerythrin conjugate (SA-PE), 
forming the detection complex. After an additional washing step, the fluorescence of 
each bead with bound SA-PE was measured when the beads were passed through 
the two laser Bio-Plex reader. The lasers provide bead classification and a reporter 
signal from PE. All incubations were carried out at room temperature. The 
fluorescence signal is detected by photomultiplier tube (PMT). The data are then 
presented as median fluorescence intensity (MFI) and concentration (pg/ml) using a  
Bio-Plex Manager™ software, where concentration is proportional to MFI of the 
reporter.    
ELISA  
Secreted PlGF concentration was detected in filtered conditioned media 24 hours and 
48 hours after irradiation using a PlGF DuoSet ELISA kit according to manufacturer’s 
guidelines (R&D Systems). The absorbance was determined with plate reader EL808 
Ultra Microplate Reader (Bio – Tek Instruments, Inc.) at 450nm excitation and 570nm 
emission, and normalized to live cell count using EVE Automatic cell counter 
(NanoEnTek).   
qRT-PCR  
Sample mRNA expression was determined at 4 hours and 24 hours after irradiation. 
Cell lysate collection and RNA isolation were performed using an RNeasy Mini Kit  
(Qiagen) according to manufacturer’s guidelines. RNA was reverse-transcribed (High 
Capacity cDNA Reverse Transcription Kit from Applied Bioscience) and cDNA was 
amplified using SYBR Green Master Mix (Roche) and the following primers: (5’-3’):  
GAPDH forward: AACGGATTTGGTCGTATTGGGC; GAPDH reverse: 
TTGATTTTGGAGGGATCTCG; PlGF forward: TGTCACCATGCAGCTCCTAA; PlGF 
reverse: AGCATCGCCGCACCTTTC; p53 forward: CCCTTCCCAGAAAACCTA; p53 
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reverse: CTCCGTCATGTCCTGTGA.  qRT-PCR was performed on LightCycler 480 
(Roche).   
siRNA transfection  
Transfection was performed by using reverse transfection with Lipofectamine 
RNAiMAX (Invitrogen) in antibiotic-free medium. Cells were re-seeded into 6-well 
plates 24h later with fresh medium supplemented with antibiotics. siLuc was 
synthesized by Microsynth with the following sequence: (5’-3’): 
CGUACGCGGAAUACUUCGATT. sip53 was purchased as a pool of four siRNAs from 
Dharmacon. Irradiation was performed 48 hours after siRNA transfection.   
Western Blotting  
Whole cell extracts were collected using Laemmli buffer and samples were boiled for 
5 minutes at 95 °C. 40-50µg of protein were separated on 10-15% SDS-PAGE gel and 
transferred to PVDF membrane. The membrane was then blocked in 5% non-fat milk 
and incubated with primary antibodies (rabbit polyclonal anti-p53 (GTX102965, 
GeneTex), rabbit monoclonal anti-p21 (2947S, Cell Signaling), rabbit monoclonal anti- 
HIF-1α (D2U3T, Cell Signaling), mouse monoclonal anti-β-actin, (A1978, Sigma)) at 
4°C overnight. After three washings, HRP conjugated secondary antibodies (mouse 
anti-rabbit (SC-2357, Santa Cruz) or sheep anti-mouse (NA931V, GE Healthcare)) 
were added for one hour at room temperature followed by additional washing steps. 
The membrane was developed with the ECL system (Amersham Bioscience) 
according to manufacturer’s protocol in Fusion FX (Vilber).     
Genomic deletion of PlGF via CRISPR/Cas9 in D341 cells  
Two separate sgRNAs targeting different regions of the third exon of PGF gene (target 
sequence 1: GAATCTGCACTGTGTGCCGG; target sequence 2:  
CGTGTCCGAGTACCCCAGCG) were generated using freely available online tools 
(UCSC and CRISPOR) and the primers were synthesized by Microsynth. The 
singlestranded oligomers were annealed and ligated into GFP and Cas9 expressing 
pLentiCRISPR-EGFP plasmid (cat. nr. 75159, Addgene, kindly provided by Beat 
Schäfer) using the Golden Gate assembly cloning strategy. The ligation mix was 
transformed into competent bacteria by heat shock. Clones with pLentiCRISPR 
plasmid was identified by colony-PCR using an U6 promoter specific forward primer 
(5’ –GACTATCATATGCTTACCGT- 3’). Positive colonies were inoculated for midiprep 
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(Sigma) culture. HEK293T (ATCC) cells were used for production of lentiviral 
constructs according to guidelines from Cellecta. Filtered lentiviral supernatant was 
used to transfect the target cells (D341). To prepare cells for FACS, live cells were 
harvested, re-suspended in PBS with 2% FBS and filtered using a 40μm cell strainer 
(BD Falcon). Cell sorting was performed with a FACSAriaTM III Cytometry System (BD 
Biosciences). Sorted cells were further subcloned through limited dilution and 
sequenced before further experiments. Each subclone was named after their 
respective well number, i.e. control cell lines C4, C6, and knock out cell lines B5, B7, 
G7and F8.   
Migration Assay  
For the transwell migration assay, 24-well transwell units (6.5mm) with 1μm pore size 
PET membranes (Greiner Bio-One, 662610) were used according to the 
manufacturer’s instructions. Briefly, 3x105 attracting cells (D341 PlGF-wt or PlGF-ko) 
were plated into the lower chamber of the transwell containing 1000μl supplemented 
with 1% FBS and without growth factors and allowed to attach for a minimum of 6h. 
The plate was sham or 5Gy irradiated. Next, 3x104 endothelial cells in 200μl of the 
same ECGM medium as above were seeded into the upper chamber of the transwell 
inserts and allowed to attach for a minimum of 6h. Thereafter, the inserts were 
irradiated with 5Gy and immediately placed on the wells harboring the attracting cells. 
The co-culture was maintained at 37°C in 5% CO2 for 48 hours. For quantification, 
cells from the upper side of the insert were scraped away with a cotton swap and 
inserts were then fixed in Methanol/Acetic Acid (75%/25%, v/v), dried and stained with  
DAPI (1:25000) in 99% MetOH. Fluorescent microscopy pictures were taken (Leica 
7000DT) and the migrated cells were counted manually in at least 3 images at 20x 
magnification per insert.   
In vivo experiments  
D341 PlGF control and PlGF knockout subclones were injected subcutaneously in the 
back of 8-week old, female athymic CD1 nude mice (Charles River) with 4 x 106 
cells/150 μl. Tumor volumes were determined with caliper according to the formula (L 
x l2)/2. Treatment started when tumors reached a volume of 150-200mm3±10%. 
Tumors were sham-irradiated or irradiated with a single dose of 5 or 10Gy for tumor 
histology using an image-guided small animal radiotherapy platform (Precision X-Ray, 
X-Rad SmART) 225kV unit with a dose rate of 3Gy/min, equipped with a cone beam  
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CT (CBCT) scanner. Precise irradiation plans were designed with the corresponding 
SmARTPlan software. Radiation therapy was applied with two opposing fields. 
Animals were kept under 3% isoflurane anesthesia for imaging and treatment. 8 days 
after treatment, mice were euthanized in a CO2 chamber, tumors were harvested and 
immediately fixed in formalin. All in vivo experiments were performed according to 
guidelines for the welfare and use of animals of the Veterinäramt Kanton Zurich, 
Switzerland.   
Immunohistochemistry  
Immunohistological endpoints were analyzed on formalin-fixed paraffin-embedded  
(FFPE) 4μm tissue sections derived from PlGF control or PlGF ko-derived tumor 
xenografts for hematoxyline and eosine (H&E), smooth muscle actin (SMA) (1:50, 
Dako, M0851) and CD31 (1:10, Dako, M0823). Images were taken on a wide-field 
Nikon Eclipse TI microscope. Amount of vessels were counted in at least 10 different 
fields in each xenograft.   
Statistical analysis  
Experiments were performed at least three times and data were analyzed using the 
unpaired Student t test and one-way ANOVA with post Tukey test using GraphPad 














Ionizing radiation increases PlGF expression and secretion across multiple 
cancer cell lines   
Secretome analysis by semiquantitative antibody array screening previously indicated 
that PlGF is secreted in response to irradiation [8]. Additional bioplex-based 
quantification of 32 major cancer biomarkers in the supernatant from irradiated A549 
lung adenocarcinoma cells now revealed that PlGF is most strongly increased in 
response to irradiation (Figure 1A). In order to analyze irradiation-induced 
PlGFexpression in more detail and across additional tumor cell lines derived from 
different tumor entities (colon, medulloblastoma, lung carcinoma), HCT116-, D341-, 
DAOY, A549-, and H125 carcinoma cells were irradiated and supernatants thereof 
analyzed for PlGF secretion 24 and 48 hours after irradiation. IR-enhanced PlGF-
secretion was identified in the conditioned media (CM) from all cell lines by ELISA in 
a time- and IRdose-dependent manner (Figure 1B-F).    
Enhanced secretion in response to irradiation might be related to IR-induced PlGF- 
expression. Upregulation of PlGF expression was observed in several cancer cell lines 
(e.g. HCT116, A549, D341) as early as 4 hours after irradiation (Figure 2), while only 
minimally or only observed in a delayed way in other cell lines (e.g. H358, FaDu, 
UW228) 24 hours after irradiation (Supplementary figure 1). Based on a literature 
search on the mutational status of Kras and p53 in these cell lines (Supplementary 
Table 1), this differential IR-induced expression pattern of PlGF could be correlated 
with the mutational status of the tumor suppressor and transcription factor p53.   
Interestingly, cells expressing wildtype p53 demonstrated IR-induced PlGF expression 
as early as 4 hours after irradiation, which correlated with early PlGF secretion. In 
contrast cells expressing mutant p53 did not show any changes in the PlGF expression 
level at this early time point after irradiation, suggesting that p53 regulates IR-induced 
PlGF expression. Of note, delayed expression of PlGF in the p53 mutated cells in 
response to irradiation correlated with delayed PlGF secretion into the CM of the 
respective cells (48 hours’ time point) (see above Figure 1).    
Due to their high PlGF expression and secretion levels, and that treatment of 
medulloblastoma patients includes radiotherapy [39], further experiments were 
primarily performed with p53 wildtype D341 cells.    
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p53 is the main regulator of PlGF in p53 wildtype cancer cells  
To determine regulation of PlGF-expression and secretion by p53, D341 and HCT116 
cells were treated with increasing concentrations of the MDM2-inhibitor MI-773. MDM2 
downregulates the transcriptional activity of p53 by direct binding to the tumor 
suppressor p53 and by ubiquitination and inducing its proteasomal degradation [40]. 
Thereby, pharmacological disturbance of the MDM2-p53 interaction might lead to p53 
stabilization and increased transcriptional activity independent of irradiation. 
Treatment of D341 and HCT116 cells with MI-773 induced PlGF-expression at an early 
time point and resulted in enhanced PlGF levels in the supernatant as determined 24 
hours after MI-773 treatment start (Figure 3A-D).   
Putative regulation of PlGF by p53 was more specifically investigated using 
p53directed siRNA. p53 mRNA and protein levels were downregulated on 
siRNAtreatment in both D341 and HCT116 cells for up to 96 hours. Likewise, 
expression of the well-known p53 downstream target p21 was also downregulated 
(Supplementary figure 3A-C). Tumor cells were irradiated 48 hours after siRNA 
transfection and PlGF secretion was determined in the CM 48 hours after irradiation. 
PlGF levels were strongly enhanced in response to irradiation in siLuc-pretreated cells, 
but basal and irradiation-induced PlGF-levels were significantly decreased in CM of 
sip53-pretreated cells (Figure 3E-F).   
MDM2 has additional binding targets besides p53 and thereby MI-773 might reactivate 
also other transcriptional activities besides p53 leading to enhanced PlGF-expression. 
Therefore, PlGF-expression and secretion was also analyzed in siRNA-
p53downregulated cells on treatment with MI-773 for 4 and 24 hours.  Neither 
expression nor secretion was enhanced by MI-773 in p53-downregulated cells. (Figure 
4A-D).  
Additional experiments were performed with the p53-inhibitor Pifithrin (PFT), which 
prevents nuclear translocation of p53 and transcriptional activation of downstream 
genes [41, 42]. Prior to irradiation, cells were preincubated with Pifithrin for 2 hours 
and the PlGF level determined 24 hours thereafter. Similar to the complementary 
experiments performed with the MDM2-inhibitor and p53-directed siRNA, decreased 
PlGF levels in Pifithrin-pretreated cells indicate p53-mediated PlGF regulation in 
response to irradiation (Figure 4E-F).   
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Overall, these complementary experiments strongly suggest that p53 is a major 
regulator for PlGF expression.  
To determine whether p53 truly binds to promoter region of PlGF, we performed 
additional ChIP-qPCR assay. Unfortunately, we could not identify p53 binding site on 
PlGF promoter using p53-antibodies and PlGF site-specific primers mentioned by 
Rashi-Elkeles et al. [38]. Binding of p53 to a different enhancer region in PlGF 
promoter is possible in another cell type.    
The effect of BAY 87-2243 on PlGF secretion under hypoxia  
Contradictory results exist on the expression of PlGF under hypoxic stress conditions, 
which might be cell type and genetic background dependent [35-37]. To investigate 
IR-induced PlGF-secretion under hypoxic conditions, D341, p53-wildtype, and DAOY, 
p53-mutated medulloblastoma cells, were irradiated followed by incubation under 
normoxic and hypoxic (1% O2) conditions. In addition, cells were pre-incubated with 
increasing concentrations of BAY 87-2243 (0nM, 10nM, 50nM) one hour prior to IR. 
BAY 87-2243 is a potent inhibitor for hypoxia-induced, HIF-1α and HIF-2α-mediated 
gene activation [43]. Due to delayed expression of PlGF in cells with mutated p53, 
secreted PlGF was determined in CM only 48 hours after irradiation. Hypoxia minimally 
enhanced basal and IR-induced PlGF secretion in the p53-wildtype medulloblastoma 
cells and cellular pretreatment with BAY 87-2243 did not interfere with PlGF secretion 
neither under normoxic nor hypoxic conditions. At the same time, cellular pretreatment 
with BAY 87-2243 abrogated IR-induced PlGF-secretion in the p53 mutated DAOY 
cells under hypoxic conditions (Figure 5A-B).  Detection of HIF1α in non-irradiated and 
irradiated DAOY cells and incubated under hypoxic conditions also demonstrated 
strongly reduced HIF-1α-levels in cells pretreated with BAY 872243 (Figure 5C).   
Control experiments were also performed with D431 cells transfected with p53oriented 
siRNA and incubated under hypoxic conditions (1% O2). Hypoxia alone did not affect 
PlGF secretion while irradiation resulted in partially enhanced PlGF secretion from 
cells incubated under hypoxic conditions. Similar to the experiments performed under 
normoxic condition, downregulation of p53 by p53-directed siRNA strongly abolished 
irradiation-induced PlGF secretion also under hypoxic condition (Figure 5D).   
These results strongly suggest differential hypoxia-dependent regulation of 
PlGFsecretion in p53-wildtype and p53-mutated medulloblastoma cells. While 
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PlGFsecretion is predominantly p53-regulated but in a HIF-signaling-independent way 
in p53-wildtype cells, interference with HIF-signaling by BAY 87-2243 downregulates 
PlGF-secretion in cells with a p53-mutated background.   
Angiogenesis is inhibited in PlGF-ko cells  
To further investigate auto- and paracrine effects of IR-induced secretion of PlGF, 
D341 PlGF knockout cells were generated using two different exon 3-targeting single 
guide RNAs of the PlGF gene and cloned into a GFP and Cas9 expressing 
pLentiCRISPR plasmid. Sequencing of the targeting region of exon 3 in our cell clones 
confirmed successful PlGF-gene targeting (Supplementary figure 3A). IR-induced 
PlGF secretion was determined in the cell supernatants derived from a control cell 
clone and a selected knock out cell clone 24 hours and 48 hours after irradiation. PlGF 
was undetectable in the supernatants of PlGF knockout cell line and IR-enhanced 
PlGF-levels were determined in the supernatants of the control cell line (PlGF-wt) 
(Supplementary figure 3B). In order to investigate a paracrine effect of PlGF, we 
performed a Boyden chamber migration assay with irradiated human umbilical vein 
endothelial cells (HUVECs) seeded in the upper chamber migrating towards 
nonirradiated and irradiated D341 PlGF-wt and D341 PlGF-ko cells, respectively. No 
quantitative difference in HUVEC migration towards unirradiated PlGF-wt versus 
unirradiated PlGF-ko cells could be determined. However, significantly increased 
migration of HUVECs towards irradiated PlGF-wt cells versus irradiated PlGF-ko cell 
could be observed (Figure 6A).    
Prior to in vivo experiments, proliferative activity and clonogenicity of PlGF-wt and 
PlGF-ko cell clones were determined and revealed only minor and PlGF-independent 
differential readouts (Supplementary figure 3C-D).    
To determine a role of IR-regulated PlGF-expression on the endothelial compartment 
in vivo, medulloblastoma xenografts were developed from subcutaneously-injected 
PlGF-wt and PlGF-ko tumor cells. Overall, 83-87% of mice injected with PlGF-wt cells 
and 52-58% of mice injected with PlGF-ko cells developed tumors. Days to reach a 
treatment volume of 150-200mm3 ranged from 31-37 days for PlGF-wt and 36-50 days 
for PlGF-ko cells respectively. Tumors were irradiated with increasing doses of IR 
(0Gy, 5Gy, 10Gy) and mice were sacrificed eight days following irradiation. Tumor 
sections were stained for H&E, CD31 and SMA and the amount of vessels were 
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counted in at least ten fields for each tumor. Microvessel densities (MVD) 
(CD31staining) in PlGF-wt and PlGF-ko medulloblastoma xenografts were 
comparable, and MVD only minimally changed in PlGF-wt tumor xenografts in 
response to irradiation. Interestingly though, a decrease in MVD was observed in 
tumor xenografts derived from PlGF-ko-medulloblastoma cells irradiated with 5Gy and 
MVD was strongly reduced on irradiation with 10Gy (Figure 6B). A quantitative similar 
outcome was determined on smooth muscle actin (SMA) staining as an indicator of 
pericyte coverage and vessel functionality (Figure 6C). Decreased pericyte coverage 
indicated increased radiosensitivity in PlGF-ko tumors. Representative stainings of 
tumor sections are shown in Figure 6D.   
PlGF-wt and PlGF-ko cells displayed comparable proliferative activity and 
radiosensitivity in vitro (see above). However, the determination of a short-time 
efficacy-oriented endpoint in vivo revealed enhanced radiosensitivity of PlGF-ko 
tumors in comparison PlGF-wt tumors. In response to 5 and 10Gy, 3 out of 5 PlGF-ko 
tumors (60%) in each group showed complete tumor regression in comparison to only 
1 PlGF-wt tumor in the group of mice treated with 10Gy of IR (Figure 7).   
Overall, these results suggest that tumor-derived PlGF has a tumor vasculature 
protective effect and thereby co-determines tumor radiosensitivity in vivo.   
  
Discussion  
Anti-angiogenic agents are mainly directed against the VEGF/VEGFR signaling 
pathway. These agents present prolonged survival, but do not cure cancer. Targeting 
the VEGF/VEGFR pathway eventually leads to resistance and to an angiogenic switch 
to other growth factors, such as PlGF, independent of VEGF [29]. The expression level 
of placental growth factor is increased in several cancer types and correlates with poor 
survival, cancer progression and resistance to therapy [19-22]. Patients with 
metastatic colorectal cancer have shown increased PlGF levels after combined 
treatment with bevacizumab, chemotherapy and radiation [44, 45]. Furthermore, 
increased PlGF expression has been linked to increased vessel number, size and 
permeability [24] and targeting of PlGF demonstrated reduced tumor vascularization 
in VEGFR-inhibitor resistant tumor model [29]. However, clinical studies with PlGF 
neutralizing antibodies did not show improved survival in combination with 
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bevacizumab in previously treated glioblastoma patients and therefore the strategy to 
target PlGF was discontinued, despite minimal normal tissue toxicities [46-48]. 
Nevertheless, and taking its undisputed but still not fully understood role in 
pathological angiogenesis into consideration, PlGF could still represent an interesting 
target for cancer treatment. However, detailed mechanistic investigations on its 
regulation alone and as part of a combined treatment modality are required.   
Here, we investigated PlGF expression and secretion in multiple cancer cell lines with 
differential genetic backgrounds in response to increasing doses of IR. 
Treatmentinduced PlGF expression could be detected in some cell lines already at 
early time point after irradiation, whereas other cell lines only responded in a delayed 
way or did not show any increase of IR-induced PlGF-expression at all. Based on a 
literature search, this differential response could be correlated with the mutational 
status of the tumor suppressor p53. At the same time, we proposed that other 
transcription factors, such as HIFs, could play a role in PlGF regulation in cells with 
mutated p53 and relevant for delayed expression in response to irradiation.   
The PlGF promoter contains binding sites for multiple transcription factors including 
p53. It has four NF-kB, five metal transcription factor 1 (MTF1), three Sp1, 1 BF2 
binding sites and a predicted hypoxia responsive element (HRE) in its promoter. 
However, all the binding sites were identified in different cell types (HEK, immortalized 
mouse embryonic fibroblasts, HeLa cells) and under different conditions [37, 49, 50]. 
First indications that p53 might regulate PlGF-expression derive from a wide-scale 
transcriptome study in normal human B-lymphoblastoid cells (TK6 cells) investigating 
the transcriptional activity of p53 in response to ionizing radiation.  Binding of p53 to 
the PlGF-promoter was also confirmed by ChIP assay but has not been further 
investigated beyond these transcriptional studies [38]. Despite several attempts we 
could not perform successful ChIP assays demonstrating direct binding of p53 to the 
promoter site of PlGF in the medulloblastoma. This might be due to technical 
limitations or the intrinsic challenge to detect direct promoter binding of p53 due to the 
multiple layers of different transcriptional regulation of p53 downstream targets in 
response to stress [51].  Nevertheless, our expression and secretion studies 
performed in multiple cell lines clearly demonstrate that p53 plays a major role in PlGF 
regulation in response to ionizing radiation.   
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In order to support our hypothesis regarding PlGF regulation by p53, we first 
demonstrated that PlGF is upregulated in response to p53 activation by other means 
than IR. Cellular treatment of p53-wt tumor cells with the MDM2 inhibitor MI-773 
stabilized p53 and subsequently resulted in increased PlGF expression and secretion 
with similar kinetics to IR-induced PlGF-expression and secretion in these p53-wt 
tumor cells. Downregulation of p53 transcriptional activity using either p53-directed 
siRNA or the small molecular p53-inhibitory compound Pifithrin corroborated 
p53mediated PlGF-expression in response to irradiation. The PlGF promoter has 
additional binding sites for other transcription factors than p53, such as NF-kB as 
mentioned above, that could also potentially be affected by MDM2. Control 
experiments with the MDM2-inhibitor with concomitant downregulation of p53, 
indicated that p53 is the major transcription factor relevant for IR-mediated regulation 
of PlGF in p53-wildtype tumor cells.   
We hypothesized that other transcription factors, mainly HIFs, could be the regulators 
of PlGF-expression in p53 mutated cells. In order to support this hypothesis, we 
investigated PlGF secretion in BAY 87-2243-treated p53 wildtype and p53 mutated 
tumor cells both under normoxic and hypoxic conditions.  While the HIF-inhibiting 
compound BAY 87-2243 did not affect PlGF under either conditions in p53-wildtype 
cells, BAY 87-2243 downregulated hypoxia-induced and IR-induced PlGF-secretion 
under hypoxic conditions in a p53-mutated background. Our results support 
investigations performed by others showing increased PlGF expression under hypoxic 
condition. Though, none of these studies demonstrate hypoxia responsive elements 
in the PlGF promoter region [49, 50, 52]. At the same time, we detect for the first time 
differential PlGF-expression in dependence on differential genetic backgrounds and 
environmental conditions, in particular p53 and hypoxia, in response to irradiation. In 
depth mechanistic investigations are now required to dissect potential competitive 
elements for PlGF regulation. Furthermore, BAY 87-2243 inhibits HIF indirectly 
through inhibition of mitochondrial complex I and decreased ROS levels [53]. Due to 
limited information about BAY 87-2243, we cannot exclude at this stage that additional 
HIF-independent mechanisms contribute to the regulation of PlGF-expression under 
hypoxic conditions in response to IR and independent of p53.      
In order to study the role of PlGF both in vitro and in vivo, D341-based PlGF knockout 
cell clones were generated, with undetectable PlGF secretion in conditioned media 
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thereof. As a functional paracrine endpoint for PlGF migration of endothelial cells was 
investigated. While no difference in endothelial cell migration towards non-irradiated 
PlGF-wt and PlGF-ko tumor cells, respectively, could be detected, increased 
endothelial cell migration was only observed towards irradiated, PlGF-secreting cells. 
These results indicated a specific paracrine (pro-)angiogenic role for PlGF under 
stress but not under basal condition.   
PlGF is known to be involved in angiogenesis [16]. Based on these IR-induced PlGF 
mediated effect in vitro, we therefore aimed to investigate its IR-induced role in 
angiogenesis and response to irradiation in medulloblastoma xenografts derived from 
PlGF-wt and PlGF-ko-cells. While tumor growth rate and basal tumor angiogenesis 
was only minimally affected by the PlGF-status, the microvessel density was strongly 
reduced in irradiation PlGF-ko tumors. Enhanced vascular radiosensitivity correlated 
with increased radiosensitivity of PlGF-ko-tumors leading to a high level of tumor 
regression in these tumors in comparison to PlGF-wildtype tumors.   
Overall, these results indicate that PlGF plays a minor role for the formation of an intact 
vasculature during tumor growth. On the other hand, PlGF has a tumor vasculature 
protective role in response to irradiation, which might be mediated by IR-induced 
secretion of PlGF from the irradiated tumor cells. Lack of this protective role could 
contribute to a microenvironment-mediated increase of tumor radiosensitivity. Thus, 
such a role for PlGF represents an interesting rationale for a combined treatment 
modality with ionizing radiation and/or chemotherapy.   
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Figure legends  
Figure 1. PlGF secretion is increased in multiple cell lines after irradiation. A) 
Bioplex-based quantification of 32 cancer biomarkers in the supernatant from 
irradiated A549 lung adenocarcinoma cells with strongly increased PlGF levels 
determined 24 hours after irradiation. B – F) Irradiation-induced PlGF-expression was 
investigated across multiple tumor cell lines derived from colon (HCT116), 
medulloblastoma (D341 and DAOY) and lung carcinoma (A549 and H125). 
Supernatants were analyzed for PlGF secretion 24 and 48 hours after irradiation. 
IRenhanced PlGF-secretion was identified in the conditioned media (CM) from all cell 
lines by ELISA in a time- and IR-dose-dependent manner. Level of PlGF secretion 
differed between different cell lines and therefore graphs show adjusted y-axis for each 
cell line. Bar graphs represent concentration of PlGF normalized to viable cell count ± 
SEM. Students t-test was used for statistical analysis.    
 
Figure 2. Relative PlGF mRNA expression is increased in response to IR. 
qRTPCR-based relative PlGF mRNA expression determined in colon (HCT116), 
medulloblastoma (D341 and DAOY) and lung carcinoma (A549 and H125) cells 4 
hours (A – E) and 24 hours (F – J) after irradiation with increasing doses of ionizing 
radiation. Early and delayed upregulation of PlGF mRNA in response to irradiation 
correlated with early and delayed PlGF secretion, respectively (Fig. 1). Bar graphs 
show PlGF mRNA expression relative to GAPDH ± SEM. Students t-test was used for  
statistical analysis.    
Figure 3.  p53 is a major regulator of PlGF-expression in response to IR.  
Treatment of D341 (A – B) and HCT116 (C – D) cells with increasing doses of the 
MDM2-inhibitor MI-773 induced PlGF-expression at 4 hours and resulted in enhanced 
PlGF levels in the supernatant as determined 24 hours after MI-773 treatment start. E 
– F) Downregulation of p53 with p53-directed siRNA abolished IR-induced 
PlGFsecretion. Cells were irradiated 48 hours after downregulation of p53 by siRNA 
targeting. PlGF secretion was determined in the CM 48 hours after irradiation. siLuc 
treated cells demonstrated a strong increase in PlGF secretion upon irradiation. Bar 
graphs show PlGF mRNA expression relative to GAPDH and PlGF secretion ± SEM. 
Students t-test was used for statistical analysis.   
Figure 4. The MDMD2-p53 axis specifically regulates PlGF expression A – D) 
PlGF expression and secretion in p53-downregulated D341 (A – B) and HCT116 (C – 
D) cells on treatment with increasing doses of MI-773 for 4 and 24 hours to investigate 
if other MDM2 targets besides p53 might be involved in PlGF regulation. E – F) 2 hours 
prior to irradiation, cells were treated with the p53-inhibitor Pifithrin (PFT). PlGF 
secretion was determined 24 hours thereafter in the CM. IR-induced PlGF secretion 
from D341 and HCT116 cells was inhibited by PFT. Bar graphs show PlGF mRNA 
expression relative to GAPDH and PlGF secretion ± SEM. Students t-test was used  
for statistical analysis.     
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Figure 5. BAY 87-2243 inhibits PlGF secretion in p53-mutated but not in p53-wt 
tumor cells under hypoxic conditions. A – B) p53 wildtype D341 and p53 mutated 
DAOY medulloblastoma cells were pre-treated with increasing doses of BAY 87-2243 
one hour prior to IR.  Following irradiation, cells were incubated under normoxic and 
hypoxic (1% O2) conditions for 48 hours and PlGF was determined in the CM by 
ELISA. C) HIF-1α protein level in BAY 87-2243 pretreated, non-irradiated and 
irradiated DAOY cells under normoxic and hypoxic conditions as determined in cellular 
lysates by western blotting. D) PlGF-secretion in siLuc- and sip53-targeted D341 cells 
incubated under hypoxic conditions (1% O2) for 48 hours following irradiation. 
Downregulation of p53 by p53-directed siRNA abolished irradiation-induced PlGF 
secretion under hypoxic condition. Graphs show secreted PlGF levels ± SEM. 
Students t-test was used for statistical analysis.    
Figure 6. PlGF protects the tumor vasculature in response to irradiation. A) The 
paracrine effect of PlGF on HUVECs was investigated by a Boyden chamber migration 
assay. HUVECs were seeded in the upper chamber and irradiated, and the amount of 
migrated HUVECs towards non-irradiated and irradiated D341 PlGF-wt and D341 
PlGF-ko cells, respectively, was determined by DAPI staining. B – C) Microvessel 
densities were determined in tissue sections from tumor xenografts derived from 
PlGFwt and PlGF-ko D341 medulloblastoma cells. Tumors were harvested 8 days 
following irradiation and tissue sections were stained for CD31- and SMA. The amount 
of vessels was counted in at least ten fields for each tumor. Each dot shows amount 
of vessels in one field. D) Representative tissue sections for each treatment group. 
Scale bar shows 50μm. One-way ANOVA and Students t-test was used for statistical  
analysis.    
Figure 7. PlGF determines medulloblastoma radiosensitivity. Tumor xenografts 
derived from PlGF-wt and PlGF-ko D341 medulloblastoma cells were sham-irradiated 
or irradiated with 5 and 10 Gy when tumors reached a volume between 150mm3 and 
200mm3. The responses of the individual tumors are depicted. In response to 5 and 
10Gy, 3 out of 5 PlGF-ko tumors of each irradiated group (60%) showed complete 
tumor regression in comparison to only 1 PlGF-wt tumor in the group of mice treated 
with 10 Gy of IR.  
 
Supplementary figure legends  
Supplementary figure 1. Relative PlGF mRNA expression is increased in 
response to IR. A – D) qRT-PCR-based relative PlGF mRNA expression was 
determined in lung adenocarcinoma (H292 and H460) cells 4 hours and 24 hours after 
irradiation with increasing doses of ionizing radiation. E – J) Minimal or no change in 
relative PlGF mRNA expression in lung adenocarcinoma (H358), head and neck 
squamous carcinoma (FaDu) and medulloblastoma (UW228) cells after irradiation. 
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Bar graphs show PlGF mRNA expression relative to GAPDH ± SEM. Students t-test 
was used for statistical analysis.    
Supplementary table 1. Correlation of genetic background of cell lines to early 
PlGF expression in response to IR.   
Supplementary figure 2. p53 is a major regulator of PlGF in response to IR. 
Downregulation of p53 with p53-directed siRNA in D341 (A) and HCT116 (B) cells. 
Relative p53 mRNA expression was determined 48-96 hours after p53 
downregulation. C) p53 protein level determined in cell lysates of D341 cells 48-96 
hours after p53 downregulation. As a control and downstream target of p53, p21 levels 
are represented following sip53 treatment. Graphs show p53 mRNA expression 
relative to GAPDH ± SEM.  
Supplementary figure 3. Generation of PlGF knockout cell lines using 
CRISPR/Cas9 system. A) A non-targeting (Ct) and an exon 3-targeting single guide 
RNA of the PlGF gene were separately cloned into the Cas9 and EGFP expressing 
pLentiCRISPR plasmids. Sequencing of the targeted region of exon 3 revealed 
successful PlGF-gene targeting. Aligned sequences of exon 3 of wildtype (upper 
sequence) and transfected cell lines (lower sequence) was compared. Successful 
knockout is shown by an insertion of a nucleotide in the knockout cell line (red square). 
B) IR-induced PlGF secretion was determined in the supernatants of the cell clones 
24 hours and 48 hours after irradiation. C) Clonogenicity and D) proliferative activity of 
PlGF-wt and PlGF-ko cell clones in response to irradiation. Experiments were 
performed once and twice, respectively.  
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4. Discussion  
4.1 Challenges in lung cancer and medulloblastoma treatments 
 
Lung cancer is an invasive, fast metastasizing cancer and the main cause of cancer 
related deaths in both men and women. Incidence and mortality of lung cancer is 
primarily associated with long term smoking and the susceptibility to carcinogenic 
substances in tobacco. It is a heterogeneous disease arising at different sites of the lung 
leading to different symptoms. The majority of patients (70%) are diagnosed at a later 
stage of the disease, with metastasis found in brain, bone or liver [226]. Lung cancers 
are categorized into two groups: 1) SCLCs that are centrally located and are the most 
dedifferentiated. They account for 15% of lung cancers, are aggressive and metastatic. 
2) The majority of lung cancers is classified as NSCLC accounting for 85%, with 5-year 
survival of 16%.  
A normal lung cell transforms into a malignant and invasive lung cancer though 
multiple stages of genetic alterations. The process continually acquiring abnormalities 
in the genome influences metastasis and treatment resistance [227]. Therefore, it is of 
great importance and clinical impact to identify and characterize these changes in 
order to provide better treatment options for patients. Currently, proto-oncogenes 
such as KRAS, EGFR and HER2 with activating mutations, rearrangements in ALK, 
several amplifications and gene overexpression among other alterations can be 
targeted [228]. Lung cancers are usually diagnosed based on symptoms which appear 
at later stages of the disease and therefore cannot anymore treated with a curative 
intent. Operable, early-stage NSCLC present 5-year survival of 50-70%. However, 
these numbers drastically drop in case of advanced disease with metastases [227]. 
Many attempts have been made in order to identify biomarkers for an early detection 
of lung cancer. However, currently there are few biomarkers in clinical use for lung 
cancer detection. Many pharmaceutical agents, such as bevacizumab and TKIs, are 
approved for lung cancer treatment in combination with radiotherapy. As in many 
therapeutic approaches for cancer, these treatment regimens lead to resistance and 
side effects. Thus, there is a need to develop a more personalized and effective therapy 
that can offer an ideal treatment.  
Additionally, tumors can alter the microenvironment to their advantage helping 
cancer cells evade the immune system. Tumor-associated immune cells help in 
supporting tumor growth. However, composition of the tumor microenvironment and 
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the subset of immune cells differ between patients and can decide treatment outcome 
[229]. Early-stage NSCLCs are primarily treated by surgically removing the tumor and 
provides best option [230]. In case of unresectable tumors, patients receive 
radiotherapy, such as SBRT [231]. Treatment modalities for patients with late stage 
and metastatic disease are radiotherapy combined with chemotherapy, targeted 
therapy and if possible, surgery [226].  
Angiogenesis plays a vital role in many cancers and represents a valuable target, 
including in NSCLC. One of the main players of angiogenesis, namely VEGF, is 
approved to be targeted by a monoclonal antibody bevacizumab as a part of first-line 
treatment in combination with chemotherapy and shows improved response rates in 
NSCLC patients. However, patients show resistance to this therapy that could be 
caused by activation of other angiogenic signaling pathways. Several drugs targeting 
these pathways are currently investigated [232]. 
Medulloblastoma arises in the cerebellum, at the base of the skull and is the most 
common childhood brain tumor affecting children between ages of 3 and 9. It accounts 
for up to 20% of pediatric brain tumors and is a leading cause of cancer-related deaths. 
Depending on the subtype of the disease, the survival of patients ranges between 40-
90% [233]. Medulloblastoma is a highly metastatic disease with symptoms that could 
lead to misdiagnoses. During medulloblastoma formation, the stem cells in the 
cerebellum stop diving and differentiating and depending on the molecular pathways 
affected, the disease can be divided into subgroups [234]. Currently, medulloblastoma 
is treated by surgically removing the tumor followed by radiation and chemotherapy 
to reduce metastasis. As mentioned above, children younger than 3 years old do not 
receive irradiation due to damages to brain. However, this could also aggravate the 
disease and survival. Hence, there is an urgent need to find new treatments that are 
well tolerated and cause fewer side effects. Targeted therapies, nanotherapies and 
inhibitors of involved pathways are developing for more effective way of treatment. An 
important issue to keep in mind is the ability of these drugs to pass the blood-brain 
barrier (BBB). BBB has been one of the main reasons to failed treatment for 
medulloblastoma since many drugs are too large to pass through [235].  
Due to different genes and pathways activated, each subgroup has differential 
response to chemotherapy. Wnt subtype is the most responsive to chemotherapy 
because of porous vessels with good overall survival rate [235].  
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Another hurdle to overcome is medulloblastoma stem cells that play an important role 
in metastasis and resistance, thereby decreasing the survival of patients [236]. In order 
to develop new drugs, we need to understand the molecular regulation of brain 
development and the pathways associated with tumor formation.  
Drugs used for medulloblastoma treatment can be divided into the following groups: 
1) topoisomerase inhibitors (e.g. irinotecan) resulting in inhibition of DNA replication 
and cell death showing prolonged survival [235], 2) Hedgehog inhibitors such as 
vismodagib that can bind to SMO and inhibit the activation, subsequently leading to 
decreased tumor size [237], 3) TKIs (e.g. imatinib) are broadly used to treat many 
cancer types where they inhibit specific signaling pathways involved in metastasis or 
cell proliferation [235], 4) PI3K/AKT signaling inhibitors with anti-proliferative 
effects in combination therapies have shown promising results [238], 5) anti-
angiogenic drugs are important in Wnt and Shh subtype as VEGF is their downstream 
target [239], [235], 6) other small molecules targeting ion channels involved in tumor 
growth [235]. 
 
4.2 The role of the tumor microenvironment in treatment response 
 
The role of the tumor microenvironment (TME) in treatment resistance to 
radiotherapy has long been investigated. 50% of cancer patients are treated with RT, 
which not only leads to cancer cell death, but also to stimulation of several processes 
in the TME. These processes include changes in tumor hypoxia, vascularization and 
secretion of growth factors to name a few. Each of these processes have been 
investigated as a potential target for treatment of cancer patients in combination with 
RT and will be discussed in this section.  
Solid tumors contain both normoxic and hypoxic regions. Hypoxia is heavily involved 
in regulating tumor growth [240] and resistance to RT [241] in these tumors. In 
response to IR, normoxic tumor cells are killed due to ROS generation and DNA 
damage. However, hypoxic regions are radioresistant due to lack of oxygen and need 
almost three times more dose of ionizing radiation as normoxic regions. In order to 
overcome this hurdle, RT is applied in fractions, killing normoxic cells e.g. around a 
tumor vessel  of the tumor, allowing time for the co-irradiated normal tissue to recover 
and the hypoxic regions of the tumor to become reoxygenated [242]. One of the main 
transcription factors upregulated under hypoxia is HIF-1α, which is further increased 
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after RT and is correlated to poor prognosis in many cancer types, such as head and 
neck cancer [243]. Many downstream targets of HIF-1α have been identified, 
including VEGF, which is involved tumor angiogenesis. Another contributor for 
increased hypoxia in tumors is abnormal tumor vasculature. When oxygen and 
nutrients do not reach all areas of the tumor due to insufficient blood vessels, HIFs are 
upregulated in the hypoxic tumor cells, which leads to increased expression and 
secretion of VEGF in order to stimulate new vessel formation. Therefore, HIFs have 
become important targets to radiosensitize tumors. Many pharmaceutical agents 
inhibit its transcriptional activity and subsequently the expression of downstream 
targets, such as VEGF, further leading to vessel normalization. This in turn leads to 
increased radiosensitivity and reduced tumor growth [108]. Other hypoxic 
radiosensitizers, such as Nimorazole, has shown promising results in NSCLC and head 
and neck cancer patients in combination with chemoradiotherapy [244]. 
One of the main factors determining the sensitivity to radiotherapy is the availability 
of oxygen, which is provided by blood vessels. Hyperfractionation with low dose per 
fraction and a high dose irradiation could have differential effects on tumor 
vasculature.  In response to low-dose hyperfractionated RT, hypoxic tumor cells 
become oxygenated and tumors regress. However, tumor vasculature is protected in 
hyperfractionated RT. Strong vascular damage was detected in xenograft models (such 
as melanoma, glioblastoma) after high-dose hypofractionated RT, which subsequently 
killed tumor cells. Some studies also show the superiority of hypofractionation to 
hyperfractionation, suggesting more vascular damage and therefore tumor cell death 
caused by high dose irradiation. At the same time, tumors irradiated with fractionated 
RT demonstrated recovered tumor vasculature. Compared to the tumor vasculature, 
the vasculature in the normal tissue is more resistant to RT, partly due to structure, 
pericyte coverage and functionality [245]. These studies could in turn explain our 
current results obtained in PlGF ko xenografts. The unprotected vasculature in PlGF-
ko xenografts were more sensitive to high doses of IR and collapsed, leading to 
regressed tumors.   
Tumor cell death by high dose IR also leads to release of tumor antigens, thereby 
stimulating an immune response [246]. IR on its own can also lead to stimulation of 
the anti-tumor immune system by upregulating surface markers and release of 
inflammatory cytokines. On the other hand, low dose hyperfractionated RT rather 
suppresses the immune system [245]. The effect of single high dose irradiation in 
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tumor models have extensively shown increased antigen presentation and anti-tumor 
immune responses, compared to fractionated regimens [245]. Improved CD8+ T cells 
generation and reduced dissemination due to better antigen presenting ability by 
dendritic cells was also reported [247]. In addition, the release of pro-inflammatory 
cytokines in response to high-dose RT augments an anti-tumor immune response 
[245]. Recent focus has been on targeting inhibitory surface molecules in order to 
boost the anti-tumor immune system and has been discussed extensively in [248-250]. 
Even though this combined therapy has shown some success, this thesis focuses on 
another aspect of combined treatment modality, namely the combination of RT with 
anti-angiogenic drugs. 
 
Antibodies and TKIs targeting angiogenesis have mainly been directed towards the 
VEGF/VEGFR pathway in combination with RT and chemotherapy showing reduced 
hypoxia and vessel normalization in many cancer types [251]. However, there are 
major drawbacks with these drugs, including normal tissue toxicity and intrinsic or 
adaptive resistance to therapy. Therefore, scheduling and dose administration of RT 
and anti-angiogenic drugs is crucial [243]. One of the first anti-angiogenic inhibitors 
is the anti-VEGF monoclonal antibody Bevacizumab approved for treatment of many 
cancer types in combination with other drugs.  
Tumor vessels usually regress in response to different types of therapies. Therefore, in 
order to keep growing and maintaining functional vessels, the tumor vasculature 
depends on pericyte coverage. In tumors treated with drugs against the VEGF/VEGFR 
pathway, most of the vessels regress, but some remain functional with pericyte 
coverage. Pericytes in turn secrete enough VEGF to support EC survival. Therefore, 
targeting pericytes with PDGFR inhibitors in combination with other anti-angiogenic 
drugs might prove helpful. However, this could in turn lead to metastatic disease due 
to a disordered vasculature [179].  
In our laboratory, we combined Bevacizumab with a novel tubulin binding agent, BAL 
27862 and BAL101553, for in vitro and in vivo studies, respectively. Under hypoxic 
condition, we observed decreased HIF-1α protein levels, decreased VEGF expression 
and secretion and inhibited tube formation in three different cell lines in vitro after 
treatment with BAL27862. Our in vivo experiments using Bevacizumab in 
combination with weekly or daily dosing of BAL101553 demonstrated a strong 
combined effect on tumor growth and vascularization. Furthermore, we combined 
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Bevacizumab and BAL101553 in paclitaxel and epothilone resistant xenografts and 
observed a superior anti-tumor effect in combination therapy compared to treatment 
with a single agent alone. These tumors presented increased tumor necrosis, inhibited 
proliferation and microvessel density in combination treatments. BAL101553 seems to 
be a promising agent for a combined treatment with Bevacizumab.  
Tumors do not only secrete VEGF, but also other growth factors such as PlGF (will be 
discussed below) in parallel [252]. Therefore, targeting VEGF might not be helpful, 
since the other growth factors can stimulate angiogenesis independent of VEGF.  
Furthermore, patients treated with chemotherapy do often not respond to anti-VEGF 
therapy. This could imply that tumors that have already received an anti-cancer 
therapy might have already adapted and thereby are resistant to an anti-VEGF 
therapy. However, the role of anti-VEGF therapies cannot be neglected in terms of 
vessel normalization, better oxygen delivery and radiosensitivity in certain cancer 
types. It also suggests that we should consider other pro-angiogenic factors as possible 
targets in cancer patients. 
 
4.3 Characterization of PlGF in ionizing radiation regulated secretome 
 
As mentioned above, RT leads to secretion of various growth factors and cytokines as 
a stress response from tumors. VEGF-A has been the main focus of research in the 
field of angiogenesis. However, recent investigations show the important role of other 
factors in angiogenesis, especially in tumors treated with anti-VEGF antibodies.  
Two former PhD students from our laboratory performed a semiquantitative large-
scale secretome analysis, investigating more than 300 biologically active factors 
released from A549 lung adenocarcinoma cell line in response to IR. This antibody 
array-based screen was reevaluated for some factors by a quantitatively more exact 
bioplex assay. Interestingly, the second member of the VEGF-family, PlGF was 
strongly increased in response to IR. Compared to VEGF, much less is known about 
the regulation of PlGF, in particular in response to treatment. Thus, in order to 
characterize PlGF in tumor cells, we investigated its secretion and expression across 
multiple cells lines with differential genetic background. Firstly, we observed an early 
rise of PlGF secretion from some of the investigated cell lines, correlated with 
increased PlGF expression as early as 4 hours after IR. However, other cells lines 
investigated only showed minimal or delayed PlGF expression. We hypothesized that 
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this could depend on the genetic background of the cells and could correlate early PlGF 
mRNA upregulation with an intact tumor suppressor gene p53. Delayed PlGF 
expression in the remaining cell lines could be regulated by other transcription factors 
(TFs), such as HIFs, in p53 mutated cells lines.   
Research about the transcriptional regulation of PlGF has been either few or 
contradictory regarding the regulation by HIF1-α [253, 254] or other transcription 
factors [255, 256], showing the necessity of further research. The transcriptional 
regulation of PlGF is not fully understood and several other factors could play a role in 
regulating its expression. In addition to HIF-1α implications in PlGF upregulation 
[257, 258], there have been studies reporting binding sites of other TFs, including p53, 
on the promoter/enhancer region of the PlGF gene. It has four NF-kB and five metal 
transcription factor 1 (MTF1) binding sites. Regulation of PlGF expression by NF-κB 
under hypoxic conditions have been demonstrated in HEK cells and could have a pro-
angiogenic role. Furthermore, NF-κB is also known to regulate VEGF-A [255]. MFT-1 
has been studied in RAS-transformed mEFs under hypoxia, also demonstrated 
increased PlGF expression [259].  
Additional factors with binding sites on the PlGF promoter/enhancer region include 
Sp1 [257], BF-2 [260] and a predicted HRE. However, cell type and conditions differ 
between these investigations. Therefore, TFs that can regulate PlGF under hypoxia 
could be cell type specific. The sole study proposing IR-induced PlGF regulation by 
p53 is a large-scale transcriptome analysis in normal human B-lymphoblastoid cells. 
Binding site for p53 on PlGF promoter was confirmed by ChIP assay but was not 
further investigated [256].  
The role of PlGF in tumor growth and metastasis is not fully investigated. Several 
studies have reported increased PlGF expression in tumor tissue compared to normal 
surrounding tissue. However, PlGF is not only secreted from tumor cells, but also from 
macrophages, endothelial cells and other cell types. Furthermore, its expression 
differs between different tumor types. Based on our in vitro secretion data, PlGF seems 
to be more relevant for treatment response. Therefore, in this PhD-project, we focused 






4.4 Differential regulation of PlGF and VEGF by TFs 
 
In order to verify that p53 is indeed the main regulator of PlGF in p53 wildtype cancer 
cells, we used different strategies to target p53 and mechanistically investigated 
downstream effects on PlGF. First, we aimed to demonstrate that p53 is regulating 
PlGF independent of IR and therefore chose to activate p53 by other means. p53 is 
constantly expressed and degraded through ubiquitination in normal and unstressed 
cells by E3 ligase mouse double minute 2 homolog (MDM2). It promotes degradation 
of p53 by attaching polyubiquitin chain on lysine residues in the COOH-terminus. This 
in turn targets p53 for proteosomal degradation. MDM2 can also negatively regulate 
p53 by directly binding to the NH2–terminus thereby blocking its transcriptional 
activity [261]. We used the compound MI-773 for MDM2 inhibition, where MI-773 
binds to the same pocket as p53 on MDM2. Following the inhibition, p53 can become 
activated and regulate the expression of subsequent downstream genes. We observed 
increase in PlGF expression at 4 hours and secretion at 24 hours similar to IR. Second, 
we treated cells with the p53 inhibitor PFT-α, which inhibits to p53 by preventing its 
nuclear translocation and transcriptional activation of downstream genes [262, 263]. 
Our results demonstrated a decrease in irradiation-induced PlGF secretion in PFT-α 
pre-treated cells. Many have investigated the mechanism of how PFT inhibits p53, 
which is still not fully understood. Some experiments show inhibition of DNA binding 
activity by PFT without any effect on the protein levels of p53, whereas others 
speculate about PFT targeting a common factor for several pathways or even inhibition 
after nuclear translocation of p53 [263-265]. Therefore, our next experiment focused 
on downregulating the mRNA and protein levels of p53 by using an siRNA approach 
to investigate if this type of specific inhibition of p53 supports our previous results. 
Both mRNA and protein expression were downregulated in sip53 treated cells, also 
showing p53-dependent downregulation of p21. We observed significant decrease in 
IR-induced PlGF secretion in p53 downregulated cells. 
Our next question rose from our previous experiments with MI-773. We speculated 
that as an inhibitor of MDM2, MI-773, could also lead to activation of other factors 
(such as MYCN, Smad3/4, NF-κB) that are usually inhibited by MDM2. The PlGF 
promoter has additional binding sites for other transcription factors than p53, such as 
NF-kB as mentioned above, that could also potentially be affected by MDM2. To 
demonstrate that p53 is the main TF relevant for IR-mediated PlGF regulation, we 
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treated p53 downregulated cells with MI-773. PlGF expression and secretion remained 
downregulated in sip53 treated cells even in the presence of MI-773.  
Our demonstration of early, IR-induced and p53-dependent upregulation of PlGF-
expression was absent in p53-mutated cells. Nevertheless, PlGF-expression was also 
present in p53-mutated tumor cells in response to increasing doses of IR but only at 
later time points. We therefore hypothesized that this effect might depend on other 
signaling pathways and aimed to investigate different signal transduction pathways 
that could potentially play a role. We decided to investigate hypoxia dependence by 
using the pharmaceutical agent BAY 87-2243. BAY 87-2243 is a mitochondrial 
complex I inhibitor and blocks the production of reactive oxygen species, which leads 
to HIF1-α inhibition [266]. Although there have been contradicting results regarding 
the link between HIF-1α and PlGF [253, 254, 257, 267-269], we observed significant 
downregulation of PlGF secretion with the HIF-1α inhibitor BAY 87-2243 under 
hypoxia in p53-mutated DAOY cells. p53 wildtype D341 cells showed an IR-dependent 
increase in PlGF secretion. However, this could not be inhibited by BAY 87-2243 under 
normoxia or hypoxia. We downregulated p53 in D341 cells to examine whether PlGF 
secretion could further be inhibited after BAY 87-2243 treatment and thereby show 
hypoxia dependence after p53 inhibition. We did not observe additional decrease in 
PlGF secretion (data not shown). This could be due to insufficient p53 downregulation 
and/or the competition between p53 and HIF-1α. Based on these results, p53 seems 
to be the dominant regulator and further support our previous experiments on p53 
dependency in D341 cells. Additionally, these results could also explain the 
inconclusive reports about PlGF regulation by HIF-1α.   
By activating and secreting angiogenic factors, tumor cells can adapt to hypoxic 
conditions as the tumor grows [270]. Expression and secretion of one of the main 
angiogenic factors, VEGF, is low under normoxia and increases in response to hypoxia. 
Decreased oxygen concentration stabilizes HIF-1α, which in turn binds to the HRE of 
VEGF leading to its activation and secretion [271]. Tumors become more invasive and 
metastatic. Therefore, the VEGF signaling pathway has become a major target for anti-
angiogenic drugs. However, in response to anti-angiogenic therapies, tumor cells 
upregulate other angiogenic factors, such as PlGF.  
Compared to PlGF regulation, wildtype p53 controls VEGF expression in an opposite 
way. According to some studies, wildtype p53 suppresses VEGF production by binding 
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and inhibiting HIF-1α during hypoxia [272, 273], although this has been contradicted 
by others [274]. In addition, in vivo models have shown increased VEGF production, 
tumor progression and increased angiogenesis in response to p53 loss of function. This 
in turn was reported to be due to the inability of mutant p53 to regulate HIF-1α [271]. 
Loss of p53 also supports NF-kB expression and inflammation, and leads to cancer 
metastasis. Furthermore, co-culturing of CAFs with p53 knockout HCT116 cells 
increased VEGF mRNA and protein expression in CAFs. CAFs are important part of 
the microenvironment and could potentially play a vital role in treatment response. 
We do not yet fully understand the interaction between CAFs and tumor cells, but it 
offers an advantageous microenvironment for cancer cells. Consequently, CAF levels 
are considered as indicators of poor prognosis in many cancer types. Taken together, 
these reports suggest a tumor promoting microenvironment due to loss of p53 [275]. 
On the other hand, wildtype p53, inactivates HIF-1a and therefore suppresses VEGF 
expression leading to decreased vascularization. 
According to our own results, in a p53 mutated background, HIFs are the major 
driving force for PlGF, which is similar to VEGF regulation. Therefore, BAY 87-2243 
can also downregulate (IR-induced) expression of PlGF, which still needs to be tested 
for VEGF. Compared to VEGF, wildtype p53 dominantly drives PlGF expression, 
which is strongly activated e.g. by external stimuli such as ionizing radiation. PlGF in 
turn could upregulate VEGF expression in the tumor. Therefore, it is possible, that 
when patients are treated with an anti-VEGF directed treatment modality, the early 
response is vessel regression. However, due to anti-angiogenic agent, wildtype p53 
status and PlGF secretion, these tumors might become resistant to therapy. The 
regulation of PlGF and VEGF by the same TFs seems to be very different.  These results 
indicate that we should consider the status of p53 in cancer cells more seriously and 
adjust treatment forms targeting pro-angiogenic factors.    
 
4.5 PlGF as a promising target for combined treatment modality 
 
PlGF has been suggested as a target for anticancer therapy due to its role in 
angiogenesis and inflammation [165]. Blockade of PlGF by neutralizing antibodies 
[164, 171, 181, 182] or gene inactivation [110, 174] resulted in reduced angiogenesis, 
inflammation, metastasis and tumor growth in several tumor models. Furthermore, 
genetic or pharmacological targeting of PlGF in medulloblastoma models showed 
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reduced tumor growth [183]. Even in spontaneous and transgenic tumor models, PlGF 
targeting demonstrated similar results as the studies mentioned above [174]. 
Additionally, a combination of anti-PlGF-directed with anti-VEGFR2-directed 
antibodies resulted in a stronger effect compared to monotherapies and also reduced 
tumor growth in anti-VEGFR2 resistant tumors [164] suggesting its significance as a 
promising target in a combined treatment modality. Apart from vessel normalization, 
inhibition of PlGF also improved the effect of chemotherapeutic agents used in 
combination therapy [164]. However, there are contradicting studies showing no 
antitumor effect of PlGF inhibition with neutralizing antibodies [174, 185, 276]. It is 
important to keep in mind that neutralizing antibodies might not have the same effect 
in vivo as in vitro. Furthermore, the response to neutralizing antibodies may depend 
on the expression of VEGFR1.  
In the second part of this project, we aimed to study the role of PlGF as a part of 
combined treatment modality in tumor angiogenesis and radiosensitivity. With 
complementary in vitro as well as in vivo experiments, we investigated the effect of 
PlGF targeting in combination with IR on tumor vascularization and radiosensitivity.  
We successfully generated GFP-expressing two PlGF wildtype control cell lines (PlGF-
wt) and four PlGF kockout cell lines by clustered regularly interspaced palindromic 
repeats (CRISPR)/Cas9 strategy. The target sequence for the first sgRNA contained a 
cysteine residue involved in intrachain disulfide bond, which plays an important role 
for the stability of the protein. PlGF secretion in all six cell lines was determined 
through ELISA and demonstrated undetectable levels of PlGF in knockout cells lines, 
even in response to IR (not included in manuscript). To investigate the paracrine role 
of PlGF, we co-cultured PlGF-wt and PlGF-ko cells with HUVECs and investigated the 
migratory capacity of HUVECs towards non-irradiated or irradiated cells. We 
observed increased number of migrating HUVECs towards irradiated PlGF-wt cells in 
response to IR. Number of migrating HUVECs towards PlGF knockout cells did not 
change. These results demonstrate a specific PlGF dependent paracrine effect in vitro 
and indicate that PlGF could be in particular important for radiotherapy-regulated 
tumor angiogenesis and could thereby also co-determine the treatment efficacy.            
Our in vivo experiments demonstrated similar MVD in both PlGF-wt and PlGF-ko 
xengtrafts. In reponse to irradiation, MVD minimally decreased in PlGF-wt 
xenografts. However, PlGF-ko xenografts revealed strongly reduced MVD in response 
to high dose irradiation. As an indicator of pericyte coverage and vessel functionality, 
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we assessed smooth muscle actin (SMA) staining in xenografts. We observed 
decreased pericyte coverage and increased radiosensitivity in irradiated PlGF-ko 
xenografts. Additionally, PlGF-ko xenografts treated with 5 or 10Gy showed regressed 
tumors in 60% of cases for each treatment group. These results in part support 
previous reports about a partially reduced vascular formation in PlGF-ko mice [174]. 
However, to our knowledge, targeting of PlGF in combination with IR has not been 
investigated so far. Based on our results, PlGF plays a protective role and could be a 
part of a rescue mechanism in response to IR, especially in the early time point of 
treatment.   
These results support the concept that PlGF plays a similar role as VEGF as previously 
demonstrate. However, one of the main differences between these two angiogenic 
factors is their expression. VEGF-A is always present in normal tissues and important 
for normal angiogenesis. It also acts as a chemoattractant for endothelial cells and 
plays a major role in new vessel formation after exercise. Therefore, targeting VEGF-
A leads to normal tissue toxicities and treatment resistance. In contrast, PlGF does not 
regulate or maintain normal vessel formation in adults and is upregulated only during 
disease. It is usually associated with poor disease outcome in several cancer types. 
PlGF only binds to VEGFR1 and with higher affinity, which means VEGF-A is 
displaced and available for VEGFR2. Thereby, a parallel and stronger angiogenic 
signaling takes place. This issue could in turn explain why anti-VEGF therapies show 
promising results at first, but fail over time due to presence of another strong 
angiogenic signaling, namely by PlGF. Furthermore, targeting VEGF-A further 
increases PlGF expression and a subsequent angiogenic signaling, where PlGF can act 
as a chemoattractant for other cells, such as macrophages, endothelial cells and 
pericytes. Pericytes recruited to newly formed vessels due to increased PlGF secretion 
leads to vessel protection and maturation. Our own results have shown decreased 
pericyte coverage and increased radiosensivity in irradiated PlGF-ko xenografts. PlGF 
also activates differentiation of macrophages into M2-like phenotype, which supports 
tumor growth by secreting more angiogenic factors [277]. PlGF is also known to 
increase VEGF-A secretion from mononuclear cells. Therefore, inhibiting PlGF would 
in turn decrease VEGF induced angiogenesis.    
Resistance to different treatment modalities, including radiotherapy, is one of the 
main drawbacks for cancer patients. There is a need to identify new biological markers 
that can be targeted in combination with radiotherapy. Patients treated with anti-
129 
 
angiogenic drugs combined with chemoradiotherapy often present increased PlGF 
levels, vessel number and permeability, which correlates with poor survival. However, 
inhibitors of PlGF have demonstrated reduced tumor vascularization without affecting 
healthy vasculature in vivo. All these results suggest PlGF as a promising target in 
cancer treatment. Though, PlGF neutralizing antibodies did not show improved 
survival in combination with Bevacizumab in previously treated glioblastoma patients 
[164, 167, 171]. However, PlGF might be a highly relevant target as part of a combined 
treatment modality, in which its “combination partner” induces the expression and 
secretion of PlGF as part of a protective stress response. Targeting of PlGF might 
thereby reduce an induced treatment threshold and sensitize for the damaging part of 
the “combination partner”, in this regard to radiotherapy. At the same time, important 
aspects to consider before treating patients with anti-PlGF antibodies alone or more 
favorable as part of a combined treatment modality, are the determination of the p53 
status of patients and previous treatments for determining therapy resistance in order 

















Approximately 50% of all cancer patients receive radiotherapy alone or in combination 
with other treatment regimens. Although ionizing radiation (IR) causes DNA damage 
and tumor cell killing, it also leads to stress responses from tumor cells leading to 
secretion of multiple factors and subsequently resistance to therapy. In this PhD 
thesis, we have shown that one of the factors secreted from cells lines derived from 
different tumor entities in response to increasing doses of IR is placental growth factor 
(PlGF). Not only secretion, but also mRNA expression of PlGF is increased across 
multiple cell lines, where early increase in mRNA expression was related to the 
transcriptional activity of the tumor suppressor p53. 
We have provided insights into regulation of PlGF by wildtype p53 through 
mechanistic investigations that have not been shown before. Unfortunately, we were 
unable to detect p53 binding sites on the PlGF promoter. This could be due to technical 
challenges, due to cell type difference and/or different p53 binding sequences. 
Therefore, it will be important to perform additional rounds of extended ChIP assays 
with multiple non-irradiated and irradiated p53 wildtype transformed und 
untransformed cells to detect specific binding of wildtype p53 to the promoter region 
of PlGF in order to further support our data.   
We briefly investigated PlGF regulation in p53 mutated cells under hypoxia and 
normoxia. Although our current experiments need to be corroborated with additional 
control experiments. We could demonstrate increased PlGF secretion under hypoxic 
conditions in p53 mutated cells in response to irradiation. This was in turn abrogated 
after treatment with the HIF-inhibitor BAY 87-2243. Future experiments for this part 
of the project should include investigations of PlGF expression and secretion in 
additional p53 mutated cell lines in response to hypoxia and IR with or without 
different classes of HIF inhibitors. As we cannot exclude additional roles of other 
transcription factors (TFs) in the regulation of PlGF expression, e.g. mutant p53, MTF1 
etc., additional experiments with different levels of hypoxia should be considered in 
order to understand the interplay between HIFs, p53 and other TFs. It is also 
important to distinguish between HIF-1α, HIF-2α or HIF-3α as the main regulator of 
PlGF under these conditions, e.g. using different HIF-ko systems or HIF-isoform 
specific downregulatory si/sh-constructs. Overall, mechanistic experiments dissecting 
the role of different, in part competing transcription factors under different conditions 
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and in different cell systems will be next steps to be addressed in order to gain deeper 
insights into the regulation of PlGF in response to irradiation.  
An additional readout for both in vitro and in vivo experiments is macrophage 
polarization. Our aim is to collect blood from healthy donor, isolate monocytes from 
the whole blood and polarize them to the M0 phenotype. Using conditioned media 
(CM) derived from our irradiated and non-irradiated PlGF knockout cells in parallel 
with positive and negative controls we can examine whether t M0 macrophage change 
their phenotype to M2-like macrophages by investigating specific gene expression in 
these macrophages. For in vivo experiments, we propose staining of tumor slices 
derived from our xenograft model with antibodies directed against surface markers for 
investigation of macrophage infiltration.  
The importance of PlGF for the treatment response to radiotherapy and IR-induced 
tumor vascularization remains crucial. PlGF is the lesser investigated member of the 
VEGF-family and to our knowledge, there are no existing data showing its IR-induced 
role and relevance neither in vitro nor in vivo. To assess this, we successfully generated 
PlGF knockout cells using the CRISPR/Cas9 system. PlGF knockout cells did only 
show minor differences in proliferative activity or clonogenecity compared to control 
cell lines in vitro. Our investigations of the paracrine role of PlGF with the migration 
assay with human umbilical vein endothelial cells (HUVECs) demonstrated increased 
migration of HUVECs towards irradiated control cells but not irradiated PlGF 
knockout cells. Additionally, our in vivo experiments revealed a corrupted tumor 
vasculature and increased tumor regression in PlGF-ko xenografts in response to 
single high doses of irradiation. increased radiosensitivity. It will be relevant to 
confirm these results with additional PlGF knockout cell lines, injected either as a 
single clones or as mixed clone populations. Furthermore, it will be of interest to 
perform similar in vivo experiments with tumor cells derived from other tumor 
entities and not only in response to single high doses of irradiation but also with 
fractionated treatment regimens.  Eventually the role of PlGF for the treatment 
response to radiotherapy will have to be investigated in more advanced complex tumor 
models, e.g. orthotopic tumor models in an immunocompetent background. Like the 
relevance of IR-induced PlGF for the treatment response will be evaluated with PlGF-
directed inhibitory antibodies. 
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PlGF is involved in pathological angiogenesis and it is of high translational relevance. 
Many cancer patients show increased levels in response to various treatments. 
Therefore, it will be of interest to obtain patient samples with known genetic 
backgrounds (specifically with regard to p53) for detailed investigations. Overall, all 
these experiments will further explain the regulation of PlGF and its IR-induced role 
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